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 Extracorporeal photochemotherapy (ECP) induces antigen-specific immune 
tolerance in graft-versus-host disease and solid-organ transplant rejection, and involves 
the ex vivo exposure of peripheral blood mononuclear cells to 8-methoxypsoralen plus 
ultraviolet A light (PUVA).  In this study, we developed an in vitro model of ECP to 
decipher the immunomodulatory mechanisms of PUVA.  The glucocorticoid-induced 
leucine zipper (GILZ) is both necessary and sufficient for the generation of 
dexamethasone-induced tolerogenic dendritic cells (DCs). We hypothesized that PUVA-
induced activation of GILZ may contribute to the immune tolerance observed after ECP 
therapy in graft-versus-host disease and solid-organ transplantation. We report that 
PUVA acts via two pathways culminating in GILZ up-regulation in human monocyte-
derived dendritic cells (MoDCs).  Firstly, PUVA directly induces GILZ expression in 
MoDCs in a dose-dependent fashion (p < 0.01).  Secondly, PUVA acts indirectly through 
the generation of apoptotic lymphocytes to induce GILZ expression in an apoptotic cell 
dose-dependent fashion (p < 0.01).  MoDCs treated with PUVA, and/or exposed to 
lymphocytes rendered apoptotic by PUVA, up-regulated GILZ, down-regulated CD80, 
CD86 and CD83, became resistant to LPS-induced maturation, increased IL-10 
production, and decreased production of pro-inflammatory cytokines (IL-12, IFN-γ, IL-6, 
TNF-α), and chemokines (IL-8, MCP-1, MIP-1β, RANTES) (all p < 0.05).  Knockdown 
of GILZ via transient transfection with GILZ siRNA, compared to scramble siRNA, 
reduced IL-10 production and increased IL-12 production, demonstrating that GILZ is 
necessary for generating this tolerogenic cytokine profile.  This study uncovers a 
potential molecular explanation for the immunomodulatory effects of PUVA, specifically 
through the induction of GILZ and polarization of immature MoDCs into tolerogenic 
DCs, and has implications for better understanding how ECP induces antigen-specific 
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1.1.   Ultraviolet Radiation 
 
 Ultraviolet (UV) radiation possesses potent immunosuppressive and anti-
inflammatory properties that were only fully appreciated with the advent of molecular 
immunology (1).  In 1974, Kripke first demonstrated that immunologic rejection of UV-
induced murine skin tumors, transplanted into syngeneic mice, could be limited by 
irradiating the recipient animal with low-dose UV light (2).  Moreover, tumor graft 
rejection could also be prevented by adoptively transferring T-lymphocytes from UV-
irradiated mice into recipient animals (2).  This finding suggested a systemic component 
to the immunosuppressive action of UV radiation, and ultimately led to the discovery of 
antigen-specific suppressor T-lymphocytes induced by UV radiation (3).  Subsequently, 
UV radiation was shown to directly inhibit various antigen-presenting cells (APCs) of the 
skin (4), including Langerhans cells (5), demonstrating the capacity of UV radiation to 
modulate both the innate and adaptive immune response.  
 Given its higher energy content, UVB radiation (280-320 nm) acts directly on 
DNA, forming pyrimidine dimers, photo-products, and ultimately inducing programmed 
cell death (1).  In contrast, UVA radiation (320-400 nm) is less energetic, and requires the 
use of photosensitizing agents to achieve similar cellular effects (1).  In 1953, Lerner 
characterized a psoralen as the photoactive compound responsible for the 
photosensitizing properties of the Ammi majus plant (1).  Approximately twenty years 
later, the combination of oral psoralens and UVA light was introduced for the treatment 
of psoriasis (6).  Then in 1987, Edelson et al. developed extracorporeal 




treat cutaneous T-cell lymphoma (CTCL) (7).  Since its initial FDA approval for CTCL, 
ECP has also been shown to be an efficacious, glucocorticoid- and immunosuppressant-
sparing treatment for a variety of diseases, including graft-versus-host disease (GVHD) 
(8), solid-organ allograft rejection (9), and autoimmune disease (10).   
 
1.2.   Extracorporeal Photochemotherapy    
ECP consists of the ex vivo exposure of peripheral blood mononuclear cells 
(PBMC) to the photosensitizing agent 8-methoxypsoralen (8-MOP) and UVA light (now 
referred to as PUVA), followed by subsequent reinfusion into the patient (7).  8-MOP 
quickly penetrates cellular and nuclear membranes, and upon absorption of UVA light, 
forms DNA mono-adducts and intra-strand cross-links in a PUVA dose-dependent 
fashion (11).  The resultant DNA damage blocks replication and transcription and 
culminates in a well-characterized pattern of lymphocyte apoptosis (12-14).  An intrinsic 
apoptotic pathway is initiated within 20 minutes of exposure to PUVA, involving reactive 
oxygen species formation, damage to mitochondrial membranes, and capsase-3, -8, and   
-9 activation (15-17).  Progressive lymphocyte apoptosis is observed over the course of 
48 hr (16, 17), primarily mediated through an extrinsic apoptotic pathway involving FasL 
and Fas receptor (CD95) interactions (18).   
Therapeutic doses of 8-MOP and UVA light were initially titrated for clinical use 
based on their ability to inhibit lymphocyte proliferation in vitro (19, 20), and doses 
generally range from 1 to 2 J/cm2 of UVA light and 100 to 200 ng/mL of 8-MOP (6-8).  
At these therapeutic doses, approximately 50 to 60% of lymphocytes are rendered 




apoptosis by 48 hr (21).  The effects of PUVA on APCs are more ambiguous, with some 
studies documenting a resistance (12, 21-23), and others a sensitivity (24-26), to 
apoptosis following PUVA treatment. 
A persistent mystery surrounding ECP centers on how a single therapy can 
stimulate an immune response to target and eradicate malignant lymphocytes in patients 
with CTCL (27), while also suppress the immune response of auto-reactive lymphocytes 
in patients with GVHD, allograft rejection and autoimmune disease (28)?  Although a 
unifying mechanism fully explaining ECP’s clinical efficacy has not yet been described, 
modulation of dendritic cells (DCs) (24, 29, 30), induction of regulatory T-lymphocytes 
(Tregs) (24, 30, 31), lymphocyte apoptosis (12-14), and modulation of cytokine release 
(32, 33) have all been implicated.   
 
1.3.   Dendritic Cells  
DCs are versatile APCs capable of eliciting robust immune responses to 
pathogenic and foreign antigens, while maintaining tolerance to benign and self-antigens 
(34-36).  The decision to elicit a specific type of immune response depends on multiple 
factors, including the maturation state of the DC (37, 38), the profile of co-stimulatory 
molecule expression and cytokine secretion, the nature of the pathogenic stimulus, the 
antigen dose presented, and the milieu of the tissue microenvironment (34-38). 
Classically, DCs mature after exposure to various danger and pro-inflammatory 
mediators, including danger-associated molecular patterns (DAMPs) and pathogen-
associated molecular patterns (PAMPs) (34, 35).  DAMPs and PAMPS are recognized by 




Mature DCs up-regulate antigen-presenting molecules, express high levels of co-
stimulatory molecules, such as CD80 and CD86, and secrete pro-inflammatory cytokines, 
such as IL-12 (35).  Mature DCs present peptides on major histocompatibility complex 
(MHC) class II molecules, and engage naïve T-lymphocytes through the T-cell receptor 
(TCR) (34, 35).  Mature DCs effectively deliver the necessary second signals (e.g. 
CD80/CD86 through CD28), and third signals (e.g. IL-12, IFN-γ, Notch ligand) required 
for naïve T-lymphocytes to differentiate into effector T-lymphocyte subsets (e.g Th1, Th2, 
Th17), thereby generating diverse immunogenic responses (34, 35).  Maturation also 
regulates the life span of DCs through CD14-mediated nuclear factor of activated T-
lymphocyte (NFAT) activation, leading to the initiation of DC apoptosis (39). 
 
1.4.   Tolerogenic Dendritic Cells 
In contrast, tolerogenic DCs are semi-mature cells (37, 38), generally characterized 
by low expression of co-stimulatory molecules, active production of IL-10 and TGF-β, 
and reduced production of pro-inflammatory cytokines and chemokines (36, 40).  
Tolerogenic DCs are critical in promoting tissue homeostasis and maintaining peripheral 
tolerance to harmless foreign antigens, as well as to self-antigens (36, 41).  Since their 
initial characterization, many agents have been investigated, with varying success rates, 
to promote the in vitro differentiation of tolerogenic DCs for therapeutic purposes in 
treating autoimmune diseases and allograft rejection (36, 40, 41).  Growth factors, 
including the immunosuppressive cytokines IL-10 and TGF-β, vitamins A and D3, 
prostaglandin E2, and retinoids have all been utilized (36, 40, 41).  Various 




cyclosporine, and tacrolimus (36, 40, 41), and protocols for genetically modifying 
immature DCs using viral vectors have been developed (40). 
Immune tolerance to self-antigens begins during development through mechanisms 
of central tolerance occurring primarily in the thymus (36).  Through the process of 
central tolerance, DCs and medullary epithelial cells delete the majority of T-
lymphocytes expressing TCRs with strong affinities for peptides derived from self-
proteins (36, 42).  In addition, some self-reactive naïve T-lymphocytes are thought to 
differentiate into Tregs, known as natural Tregs (42).  Central tolerance mechanisms are 
overwhelmingly successful in preventing the vast majority of autoimmune disease (42).   
Nevertheless, some auto-reactive T-lymphocytes escape the thymus and enter peripheral 
tissues (42).  Tissue damage and cellular necrosis, resulting from periods of inflammation 
and infection, release self-proteins that are not adequately represented in the thymus and 
which T-lymphocytes may potentially target in an auto-reactive fashion (41, 42).  
Peripheral tolerance mechanisms are then required to suppress immune responses to these 
exposed self-antigens, as well as to harmless foreign antigens, non-pathogenic 
commensal organisms in the lung and digestive tract, and antigens in immunologically 
privileged sites, such as the anterior chamber of the eye and testes (41).  
To maintain peripheral tolerance to these antigens, tolerogenic DCs induce auto-
reactive T-lymphocyte deletion and anergy, and also generate antigen-specific Tregs (36, 
41, 42).  Tolerogenic DCs present peptides on MHC-class II molecules, and in a similar 
manner as immunogenic DCs, engage naïve T-lymphocytes through the TCR (36, 41).  
However, TCR ligation and downstream signaling in the setting of limited, or absent, 




results in T-lymphocyte deletion or anergy (40-42).  Deleting auto-reactive T-
lymphocytes, or rendering them anergic and unable to respond to the presented antigen in 
future settings, enables tolerogenic DCs to establish peripheral tolerance to the presented 
antigens (41, 42).  Furthermore, Tregs are critically important in maintaining peripheral 
tolerance, and generally are CD4+CD25+ T-lymphocytes expressing the Foxp3 
transcription factor (43).  Tolerogenic DCs present peptide in the context of active IL-10 
and TGF-β secretion (42, 43), rendering them uniquely capable of generating antigen-
specific Tregs both in vitro and in vivo (43, 44).   
Multiple lines of evidence suggest that the induction of antigen-specific Tregs by 
tolerogenic DCs contributes to the therapeutic efficacy of ECP (24, 31).  Firstly, in vivo 
murine models of ECP demonstrate that an infusion of ECP-treated donor cells 
significantly reduces established GVHD (45) and prolongs cardiac allograft survival (46, 
47), through the generation of antigen-specific CD4+CD25+Foxp3+ Tregs (45, 47).  In the 
GVHD model, Gatza et al. report that in addition to increased numbers of Foxp3+ Tregs 
derived from the donor’s T-lymphocytes and bone marrow grafts, there was a 
corresponding decrease in the number of donor effector lymphocytes that had never been 
themselves exposed to PUVA (45).  Thus, through both donor effector T-lymphocyte 
deletion and Treg formation, the donor’s T-lymphocytes were rendered tolerant of 
foreign antigens within the recipient animal (45).  In the cardiac allograft models, ECP-
treated donor cells similarly delivered both donor alloantigen and regulatory signals to 
DCs of the transplant recipient (46, 47).  The systemic anti-donor T- and B-lymphocyte 
responses were greatly decreased, in part through T-lymphocyte deletion and Treg 




Secondly, ECP inhibits both the sensitization and effector phase of contact 
hypersensitivity, through the induction of Tregs and generation of IL-10, respectively 
(48).  Thirdly, ECP was accompanied clinically by an increase in the percentage of 
circulating CD4+CD25+Foxp3+ Tregs, from 8.9% to 29.1%, in ten patients with GVHD 
(49).  Lastly, prolonged ECP has not been observed to increase the incidence of 
opportunistic infection or malignancy (24), and T-lymphocyte and B-lymphocyte 
responses to novel or recall antigens are conserved in ECP patients (50).  Both of these 
observations suggest that antigen-specific effects, rather than global immunosuppression 
as seen with chronic glucocorticoid administration, are operating in vivo after ECP. 
Classically, tolerogenic DCs were described as both phenotypically and 
functionally immature cells (36, 37).  The original model by Steinman et al. stated that 
immature DCs present low levels of self-peptide in the context of low co-stimulatory 
molecule expression, and thereby mediate tolerance to self-antigens (34-36).  This model 
was subsequently refined with the discovery of co-inhibitory molecules (37), including 
B7-H1 (programmed death ligand 1) and immunoglobulin-like transcript 3 (ILT-3), and 
with the realization that tolerogenic DCs actively secrete immunosuppressive molecules, 
including IL-10 and TGF-β (38).  It is now evident that tolerogenic DCs are both 
phenotypically and functionally mature cells and perform specialized functions, 
analogous to immunogenic DCs (37, 38, 40).  Thus, the paradigm of DC maturation as 
the critical switch between tolerance induction and immunity is no longer strictly valid.  
The term ‘semi-mature,’ has been coined to differentiate the unique phenotypic and 






Apart from the questionable susceptibility of monocytes and DCs to apoptosis 
following ECP (12, 21-26), only a handful of studies have investigated the direct effects 
of ECP on monocyte and DC function.  Studies examining the effects of ECP on these 
cell types have relied on procuring cells after treatment, or by irradiating cells in vitro 
using a UV light box.  In one study, irradiated leukocytes from patients with chronic 
GVHD were isolated from the ECP bag after treatment (51).  When these irradiated 
leukocytes were co-cultured with monocytes isolated before ECP from the same patient, 
production of both IL-10 and IL-1 receptor antagonist (IL-1Ra) were markedly increased 
(51, 52).  Increased IL-10 production by monocytes was also observed following ECP in 
a separate analysis (23), along with reduced CD54, CD40 and CD86 co-stimulatory 
molecule expression (23).  Likewise, an in vitro model of ECP designed by Legitimo et 
al. consisted of the co-culture of PUVA-treated monocytes with untreated monocytes in a 
nine to one ratio in an attempt to reproduce the extracorporeal exposure of approximately 
10% of circulating monocytes to PUVA (53).  In this model, the authors observed 
increased HLA-DR expression and endocytic capacity in the untreated monocytes, and a 
reduced ability to induce allogeneic T-lymphocyte proliferation (53).   
Concerning the effects of ECP specifically on DC function, Spisek et al. analyzed 




refractory chronic GVHD (21).  The authors reported significant production of IL-10, and 
virtually no IL-6 or IL-12 production by myeloid DCs after treatment (21).  Another 
study also reported a decreased alloreactive capacity of DCs isolated after ECP (54), and 
a shift from a predominately Th1 (IFN-γ) to Th2 (IL-10 and IL-4) cytokine profile in 
patients with chronic GVHD (54).  Finally, Berger et al. demonstrated that the ECP 
procedure itself induces monocyte-to-DC differentiation within a single day (29).  The 
DCs produced during ECP were maturationally synchronized and functionally capable 
APCs (29), further suggesting that DCs play a central role in the therapeutic efficacy of 
ECP. 
 
1.5.   Glucocorticoid-Induced Leucine Zipper 
 Glucocorticoids have long been known to modulate APC function both in vitro and 
in vivo (55).  Human DCs treated with dexamethasone increase mannose-receptor 
mediated endocytosis (56), reduce expression of the maturation molecule CD83 and the 
co-stimulatory molecule CD86 (55), increase production of IL-10 (57), and reduce 
production of IL-12 (57).  Dexamethasone treatment also induces durable effects, with 
increases in IL-10, and decreases in IL-12, maintained for up to 5 days after removal of 
dexamethasone from DC cultures (58). 
Until recently, the molecular signals driving an immature DC to be committed 
towards a tolerogenic phenotype and functional state were unknown.  In 2006, Cohen et 
al. described an intracellular gene and protein product, highly expressed in human DCs 
after dexamethasone treatment, that was pivotal for the tolerogenic functions of DCs (59).  




domain family protein 3), was originally identified as a dexamethasone-responsive gene 
that protected murine T-lymphocytes from TCR/CD3-activated cell death (60).  T-
lymphocytes over-expressing GILZ demonstrated pronounced inhibition of TCR-
activated nuclear factor κB (NF-κB), IL-2 production, FasL up-regulation, and ultimately 
activation-induced apoptosis (61).  A variety of immunologic and non-immunologic cell 
types were subsequently discovered to also express GILZ, including macrophages (62), 
mast cells (63), bone marrow mesenchymal cells (64), and epithelial cells (65, 66).  To 
date, GILZ has been implicated in an equally diverse number of cellular processes, 
including spermatogenesis (67), renal ion transport (65, 66), neuroendocrine functioning 
(68), and osteogenic differentiation (64). 
 In the original report by Cohen et al., over-expression of GILZ by plasmid 
transfection, and silencing of GILZ with siRNA revealed that GILZ is both necessary and 
sufficient for the generation of tolerogenic human DCs (59).  The expression of GILZ is 
also induced in vivo in patients receiving glucocorticoids (59).  In a follow-up study by 
Hamdi et al., human DCs expressing GILZ were found to be capable of inducing antigen-
specific Tregs, and GILZ was necessary for this induction (69).  The authors postulated 
that GILZ may be a molecular switch committing immature DCs towards the tolerogenic 
differentiation pathway (59, 69) .  According to this model, immature DCs do not express 
GILZ until exposed to immunosuppressive stimuli, such as glucocorticoids, IL-10, or 
TGF-β (59).  Once GILZ is expressed at high levels, immature DCs differentiate into 
semi-mature tolerogenic DCs capable of generating Tregs and maintaining immune 
tolerance (59, 69).  If immature DCs are instead exposed to traditional maturation stimuli, 




differentiate into mature immunogenic DC, capable of eliciting classical Th1, Th2, Th17 or 




 Human DCs expressing GILZ down-regulate co-stimulatory molecules and 
maturation markers (59, 70, 71), up-regulate molecules involved in maintaining 
peripheral tolerance, including PD-L1 and ILT-3 (70, 71), increase production of IL-10, 
reduce production of pro-inflammatory cytokines and chemokines, and are poor inducers 
of CD4+ effector T-lymphocyte responses (59, 69-71).  In addition, human DCs 
expressing GILZ generate IL-10 producing CD4+CD25+Foxp3+ Tregs, capable of 
inhibiting CD4+ and CD8+ T-lymphocyte responses in an antigen-specific manner (69).  
In fact, the antigen-specific tolerance-inducing capacity of GILZ is exerted mainly 
through Treg induction (69-71). 
In humans, GILZ codes for a cytosolic protein that directly binds to, and inhibits, a 
wide variety of signaling pathways that are highly active during inflammation, and in 
immunogenic DCs after ligation of TLRs, cytokine receptors, and chemokine receptors 
(70, 71).  Specifically, GILZ binds to the p65 subunit of the prominent pro-inflammatory 
transcription factor NF-κB, preventing its nuclear translocation, DNA binding capacity, 




(MAPK) family members Ras/Raf-1 (61, 67, 71), and ERK-1/2 (70, 71), and the activator 
protein 1 (AP-1) (70, 71).  Given the importance of signal transduction pathways in 
integrating and amplifying cellular responses to pathogens and pro-inflammatory 
cytokines, the role of GILZ as a direct inhibitor of these pathways points towards its 
fundamental role as a regulator of the immune response (70, 71). 
The expression of GILZ is induced to a lesser extent by both IL-10 and TGF-β 
(59).  Like glucocorticoids (55-58), IL-10 blocks the maturation of DCs, reducing the 
expression of co-stimulatory molecules and the production of IL-12 (73), and TGF-β is 
critical for Treg induction (43).  These observations suggest that GILZ may be a common 
molecular switch committing DCs towards a tolerogenic phenotype and functional state 
after exposure to diverse immunosuppressive stimuli (59, 69).  While glucocorticoids 
bind to the glucocorticoid receptor, which transactivates the expression of glucocorticoid 
target genes including GILZ (70, 71), the molecular pathways linking IL-10 and TGF-β 
signaling to the induction of GILZ remain unknown.   
 
1.6.   Apoptotic Cells 
The uptake of apoptotic cells by resident DCs not only maintains tissue 
homeostasis, but is also thought to induce peripheral tolerance through the presentation of 
self-antigens derived from apoptotic cells (41, 42).  The ability of apoptotic cells to 
deliver immunosuppressive signals to APCs and reduce a pro-inflammatory response is 
also well documented (74-76).  The extent of immunosuppression conferred by apoptotic 
cells depends on the nature of the apoptotic material (75, 76), the level of cellular 




administration (74, 75).  Voll et al. first reported that monocytes, in the presence of 
apoptotic cells, increase production of IL-10 and decrease production of the pro-
inflammatory cytokines TNF-α, IL-1β and IL-12 (74).  Cell-contact was later 
demonstrated to be necessary for the induction of this immunosuppressive cytokine 
response (75).  Moreover, monocytes cultured with ECP-treated apoptotic lymphocytes 
reduce production of the pro-inflammatory cytokines IL-1α (21, 32) and IL-6 (21, 32), 
and increase production of IL-10 (23, 52) and IL-1Ra (51, 52). 
 Similarly, apoptotic cells have been observed to modulate the functions of both 
macrophages (78) and DCs (77-79).  Immature DCs are capable of recognizing and 
internalizing PUVA-treated cells undergoing apoptosis (31, 45-47).  After internalizing 
apoptotic cells, DCs acquire a tolerogenic phenotype (53, 80, 81), down-regulate 
expression of co-stimulatory molecules (80, 81), increase production of IL-10 (48, 79, 
81), and become poor stimulators of naïve T-lymphocytes (79-81).  The downstream 
molecular pathways contributing to the induction of tolerogenic DCs by apoptotic cells 
remain unclear, however receptors involved in the recognition and uptake of apoptotic 
bodies are likely involved (74).   
The exposure of phosphatidylserine on the outer leaflet of the plasma membrane 
and loss of membrane phospholipid asymmetry is one of the earliest cellular events 
occurring during apoptosis (82, 83).  Phosphatidylserine is recognized by TAM (Tyro3, 
Axl and Mer) receptors on the surface of DCs (84), and through a combination of the 
thrombospondin receptor (CD36) (78) and other scavenger receptors, including the 
vitronectine (αVβ3 integrin) receptor (74), DCs recognize and internalize apoptotic cells.  




immunosuppressive signals, as evidenced by the ability to mimic the inhibitory effects of 
apoptotic cells with only phosphatidylserine-containing liposomes (85) or anti-CD36 (83).  
In summary, ECP induces antigen-specific immunosuppression in GVHD (45) and 
solid-organ transplant rejection (46, 47), and this immunomodulation is largely mediated 
through the generation of antigen-specific Tregs (45-48).  Moreover, both UV radiation 
(1, 2) and apoptotic cells (74, 77-79) transmit immunosuppressive signals to DCs, and the 
phenotypic and functional characteristics of tolerogenic DCs are essential for inducing 
Tregs differentiation from naïve T-lymphocytes (41-43).  Given this set of observations, 
combined with the central role of GILZ in generating tolerogenic DCs (59) and Tregs 
(69), we hypothesized that PUVA directly induces GILZ expression in immature DCs, 
thereby polarizing them towards a tolerogenic phenotype and functional state.  We 
further hypothesized that the immunosuppressive signals delivered by lymphocytes, 
rendered apoptotic by PUVA, induce GILZ expression in a similar fashion as 
glucocorticoids, IL-10 and TGF-β.  We developed a co-culture of human monocyte-
derived DCs (MoDCs) and apoptotic lymphocytes (ApoL) as an in vitro model of ECP to 











Hypothesis A:  PUVA directly induces GILZ expression in immature MoDCs in a dose-
dependent fashion and polarizes MoDCs towards a tolerogenic phenotype and function. 
Hypothesis B:  PUVA indirectly induces GILZ expression through the generation of 
ApoL that are subsequently recognized by immature MoDCs.  ApoL induce GILZ 




Specific Aim 1:  To differentiate human monocytes into immature MoDCs in the 
presence of GM-CSF and IL-4, and determine the dexamethasone dose-dependent 
induction of GILZ to serve as a positive control. 
Specific Aim 2:  To quantify the susceptibilities of immature MoDCs and lymphocytes to 
the apoptotic effects of PUVA.   
Specific Aim 3:  To determine if PUVA treatment and apoptotic cell exposure induces 
GILZ expression in immature MoDCs. 
Specific Aim 4:  To characterize the phenotypic profile of MoDCs expressing GILZ at 
high levels after PUVA treatment and/or apoptotic cell exposure, including expression of 
the maturation marker CD83, and the co-stimulatory molecules CD80 and CD86. 
Specific Aim 5:  To characterize the functional profile of MoDCs expressing GILZ at 
high levels after PUVA treatment and/or apoptotic cell exposure, including production of 
IL-10 and various pro-inflammatory cytokines and chemokines, including IL-12. 
Specific Aim 6:  To establish if GILZ induction is responsible for the tolerogenic 
cytokine profile observed after PUVA treatment and/or apoptotic cell exposure, 





3.1.     Authorship 
 JSF formulated the hypotheses regarding the induction of GILZ after exposure of 
MoDCs to PUVA and apoptotic cells.  JSF, in collaboration with RLE, RET and JC, 
designed all experiments to provide laboratory support for these postulates.  JSF 
performed all of the methods, procedures and experiments described below.  JSF, along 
with RLE, RET and JC, analyzed and interpreted the data.   
 
3.2.   Sample Collection  
 
 Whole blood was acquired from healthy subjects under the guidelines of the Yale 
Human Investigational Review Board, and informed consent was provided according to 
the Declaration of Helsinki.  Peripheral blood specimens were obtained by standard 
venipuncture into syringes containing 0.1% heparin, and PBMC were isolated by 
centrifugation over a Ficoll-Hypaque gradient (Isolymph, CTL Scientific, Deer Park, 
NY).  Cell viability was assessed by Trypan blue exclusion and PBMC were utilized 
immediately after isolation.   
 
3.3.   Monocyte Enrichment  
 
 Freshly isolated PBMC were plated in 6-well polystyrene tissue culture plates at a 
concentration of 5 x 106 cells/mL in RPMI-1640 (Gibco, Carlsbad, CA) supplemented 
with 15% heat-inactivated human AB serum (Gemini, Sacramento, CA), L-glutamine, 
and 25 mM HEPES.   Monocytes were allowed to adhere to the plastic culture plate for 2 




were vigorously washed with RPMI-1640 and incubated for an additional 1.5 hr at 37oC 
and 5% CO2.  Non-adherent cells were once again removed, and adherent cells were 
vigorously washed as previously described.  The purity of adherent and non-adherent 
cells was determined by CD14 and CD3 flow cytometric staining (purity: 71.6 ± 5.6% 
CD14+).  Non-adherent cells (purity: 66.0 ± 4.5% CD3+) removed during plastic 
adherence will now be referred to as lymphocytes. 
 Monocytes were also enriched from freshly isolated PBMC by negative selection 
using the Monocyte Isolation Kit II (Miltenyi Biotec, Auburn, CA) according to the 
manufacturer’s instructions, with the following modification:  The purification buffer was 
optimized to PBS supplemented with 2% autologous serum and 1 mM EDTA.  Isolation 
of unlabeled monocytes was achieved by negatively depleting the magnetically labeled 
cells incubated with an antibody cocktail consisting of anti-human CD3, CD7, CD16, 
CD19, CD56, CD123 and glycophorin A.  The purity of enriched cells was determined 
by CD14 flow cytometric staining (purity: 83.8 ± 3.8% CD14+).   
 Finally, monocytes were enriched from freshly isolated PBMC by CD14 positive 
magnetic bead selection according to the manufacturer’s instructions (Miltenyi Biotec, 
Auburn, CA), with the following modifications: 1.) The purification buffer was optimized 
to PBS supplemented with 0.5% AB serum and 2 mM EDTA; 2.) 20 µL FcR blocker 
(Miltenyi Biotec, Auburn, CA) was added to 107 cells and incubated for 10 min on ice; 
3.) 2 µL anti-human CD14 -biotin labeled antibody (clone 61D3, eBioscience, San Diego, 
CA) was then added to 107 cells and incubated for 20 min on ice; 4.) After washing with 
purification buffer, 20 µL anti-biotin microbeads (Miltenyi Biotec, Auburn, CA) were 




separator column in a magnetic field (Miltenyi Biotec, Auburn, CA).  Magnetically 
labeled CD14+ monocytes were retained in the column, and the unlabeled cells were 
washed off and saved.  After removal of the column from the magnetic field, 
magnetically labeled CD14+ monocytes were eluted as a positively selected fraction.  The 
purity of enriched cells was determined by CD14 flow cytometric staining (purity: 88.1 ± 
3.5% CD14+). 
 
3.4.   Generation of Immature Monocyte-Derived DCs 
 Enriched monocytes were cultured at a density of 5 x 106 cells/mL in 6- and 12-
well polystyrene tissue culture plates at 37oC and 5% CO2 in RPMI-1640 supplemented 
with heat-inactivated 15% human AB serum and 1% penicillin/streptomycin (now 
referred to as complete media).  800 IU/mL recombinant human GM-CSF (R&D 
Systems, Minneapolis, MN) and 1000 IU/mL recombinant human IL-4 (R&D Systems, 
Minneapolis, MN) were added to cultures for 36 hr to induce monocyte to immature DC 
differentiation as described (86).  In comparative studies, MoDCs generated in 48 hr are 
comparable with traditional MoDCs (87, 88) cultured for 5 days both phenotypically and 
functionally (88, 89), and equally capable of eliciting T-lymphocyte responses in vitro 
(86).  After 36 hr, the immunophenotype of cells was analyzed to ensure that they 
possessed an immature MoDC phenotype. 
 
3.5.   8-MOP and UVA Light Treatment 
 Cultures were incubated with 20 µg/mL 8-MOP (Therakos, Raritan, NJ) for 30 




12 linear fluorescent tubes.  Cells were washed once with PBS after treatment, and 
replaced with fresh complete media.  The tubes emitted UVA light ranging from 320 to 
400 nm, with a peak emission of 365 nm.  The UVA irradiance (power, W/m2) was 
measured using a photodiode, removing visible light (>400 nm) with a low-pass filter.  
The radiation emission of the lamp and the transmission characteristics of the media and 
plastic plates used for cell culture were evaluated in order to determine their absorption 
properties.  Given a measured irradiance emitted from the fluorescent tubes, and the 
absorption properties of the various components of the system, it was possible to 
determine the time (sec) needed to expose the cells to deliver a given dose of UVA 
radiation (J/cm2).  A direct comparison between RPMI-1640 with or without phenol red 
revealed no difference in the kinetics of lymphocyte apoptosis, and RPMI-1640 with 
phenol red was chosen for all experiments involving 8-MOP and UVA light.  
 
3.6.   MoDC/Lymphocyte Co-Cultures  
 Cultures of MoDCs and lymphocytes were treated with PUVA independently.   
Lymphocytes were treated with 8-MOP (100 ng/mL) and UVA light (1 J/cm2), washed 
once with PBS, counted, and co-cultured with either PUVA-treated or untreated MoDCs 
in a ratio of five or ten lymphocytes to one MoDC.  PUVA-treated and untreated MoDCs 
were also cultured alone, with no lymphocytes added.  MoDCs treated for 24 hr with 100 
nM dexamethasone (Sigma, Ronkonkoma, NY) were chosen as the positive control group 
(59).  All cells were cultured at 37oC and 5% CO2 in complete media.  After 24 hr, cells 
from all groups were harvested and MoDCs were re-purified.  Given that lymphocytes 




RNA was not isolated in significant quantity from lymphocytes.  MoDCs were re-
purified using CD11c magnetic bead positive selection (purity: 96.4 ± 1.0% CD11c+, 3.2 
± 1.1% CD3+ cell contamination) according to the manufacturer’s instructions (Miltenyi 
Biotec, Auburn, CA).  The CD11c positive magnetic bead selection was performed in an 
identical fashion as previously described for the CD14 positive magnetic bead selection 
of monocytes.  CD11c+ MoDCs were then re-plated at 0.5 to 1.0 x 106 cells/mL in 
complete media and stimulated with 100 ng/mL lipopolysaccharide (LPS, from E. coli 
026:B6) (Sigma, Ronkonkoma, NY).  24 hr after LPS stimulation, cells were harvested 
for RNA isolation and flow cytometric analysis, and supernatants were collected for 
cytokine quantification.  Parallel groups not receiving LPS were also analyzed.   
 
3.7.   siRNA-Mediated GILZ Knockdown 
 Silencer select pre-designed (inventoried) and validated GILZ siRNA (Invitrogen, 
Carlsbad, CA; TSC22D3, sense: GCUUUGGGAUGACCGCUUAtt, antisense: 
UAAGCGGUCAUCCCAAAGCtg), with off-target prediction algorithms, was used to 
transiently knockdown GILZ expression in MoDCs.  MoDCs were transfected using the 
Lipofectamine RNAiMAX Reagent according to the manufacturer’s instructions 
(Invitrogen, Carlsbad, CA).  Opti-MEM I Reduced Serum Medium (Invitrogen, Carlsbad, 
CA) was used to incubate diluted RNAi duplex and lipofectamine reagent for 20 min at 
room temperature.  RNAi duplex-lipofectamine complexes were then added to MoDC 
cultures and incubated for 2 hr at 37oC and 5% CO2.  Transfected MoDCs were treated in 




also transfected with scramble siRNA as a control.  Each group contained a culture that 
was not transfected.  Transfection efficacy was determined by qRT-PCR. 
 
3.8.   Immunophenotyping 
 Monoclonal antibodies specific for monocytes and DCs included: HLA-DR FITC 
(Beckman Coulter, Brea, CA; clone Immu-357), CD80 FITC (Beckman Coulter, Brea, 
CA; clone MAB104), CD83 PE (Biolegend, San Diego, CA; clone HB15e), CD3 PE 
(Biolegend, San Diego, CA; clone OKT3), CD86 PE (Biolegend, San Diego, CA; clone 
IT2.2), GILZ PE (eBioscience, San Diego, CA; clone CFMKG15), CD14 PerCP/cy5.5 
(eBioscience, San Diego, CA; clone 61D3), and CD11c APC (Biolegend, San Diego, 
CA; clone 3.9).  Antibodies were used at their pre-determined optimal dilutions and 
staining was performed in the dark in FACS buffer (PBS plus 1% AB serum).   
 Apoptosis was assessed using the Annexin-V Apoptosis Detection Kit 
(eBioscience, San Diego, CA), according to the manufacturer’s instructions, with 7-AAD 
substituting for PI as the cell viability dye.  Annexin-V binds phosphatidylserine on the 
surface of apoptotic cells as the cell loses the ability to maintain membrane phospholipid 
asymmetry (82).  Phosphatidylserine exposure is the one of the earliest events that occurs 
once a cell begins the process of apoptosis (82, 83).  7-AAD has a strong affinity for 
nuclear DNA, and is an indicator of cell membrane integrity.  When a cell is in a late 
stage of apoptosis, or is undergoing secondary necrosis, the integrity of the cell 
membrane may become compromised, and the cell’s DNA will stain with 7-AAD.  Cells 
displaying an Annexin-V+/7-AAD- phenotype were classified as early apoptotic cells, and 




 Dual membrane and intra-cytoplasmic staining was performed using the IntraPrep 
fix and permeabilization kit (Beckman-Coulter, Brea, CA), according to the 
manufacturer’s instructions.  Intracytoplasmic staining was performed with GILZ and 
CD83.  Background staining was established with appropriate isotype and fluorescence 
minus one controls.  Immunofluorescence was analyzed using a FACSCalibur L (BD 
Biosciences, San Jose, CA) within 2 hr of fixation with 2% paraformaldehyde.  A 
minimum of 10,000 events were collected for each group.  Raw data was analyzed using 
FlowJo software (TreeStar, Can Carlos, CA). 
 
3.9.   Quantitative Real-Time PCR 
 RNA was isolated from CD11c+ MoDCs using QIAShredder columns (QIAGEN, 
Hilden, Germany) and the RNeasy Mini Kit (QIAGEN, Hilden, Germany), with on-
column Dnase I treatment (QIAGEN, Hilden, Germany), according to the manufacturer’s 
instructions.  RNA yield and purity were assessed using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE).  The A260/280 ratio of 
isolated RNA was consistently between 1.8 and 2.1, with RNA yields ranging from 100 
ng to 5 µg.  Up to 1 µg of RNA was immediately reverse transcribed to cDNA using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Middletown, CT) 
according to the manufacturer’s instructions.  Reverse transcription was performed in a 
96-well thermocycler (MJ Research PTC-200, Waltham, MA), with the following run 
conditions: 25o C (10 minutes), 37o C (120 minutes), 85o C (5 seconds).   TaqMan real-
time PCR was used to detect transcripts of GILZ, HPRT-1, CD80, and CD86.  Primers 




Assays (Applied Biosystems, Middletown, CT).  SYBR green real-time PCR with Power 
SYBR Green Master Mix (Applied Biosystems, Middletown, CT) was used to detect 
transcripts of IL-12, IL-10, IL-6, TNF-α, TGF-β and GAPDH.  Primers were designed to 
span intron junctions using Primer3Plus and the CCDS consensus sequence for each 
gene.  Primer melting curves were obtained to confirm a single product and exclude 
primer-dimer formation.  HPRT-1 and GAPDH were used as reference genes.  Samples 
were run in triplicate on a 7500 Real Time PCR System (Applied Biosystems, 
Middletown, CT), and raw data was analyzed using 7500 Software v.2.0.5.  The delta-
delta C(t) method was used to calculate the fold change relative to control cells.  Primer 
sequences are listed below for each gene. 
IL-6 - PrimerF: GAGCTGTGCAGATGAGTACAAAA; PrimerR: GCATTTGTGGTTGGGTCAG 
IL-10 - PrimerF: TCCCTGTGAAAACAAGAGCA; PrimerR: TGTCAAACTCACTCATGGCTTT 
IL-12a - PrimerF: CAAGACCATGAATGCAAAGC; PrimerR: TCAAGGGAGGATTTTTGTGG 
IL-12b - PrimerF: TGACATTCTGCGTTCAGGTC; PrimerR: CATTTTTGCGGCAGATGAC 
TNF-α - PrimerF: GACAAGCCTGTAGCCCATGT; PrimerR: GAGGTACAGGCCCTCTGATG 
TGF-β - PrimerF: GGCTTCTTGGTGCTGATGTC; PrimerR: TGCTTGGCAAACTCAGTGTC 
GAPDH - PrimerF: CAATGACCCCTTCATTGACC; PrimerR: GACAAGCTTCCCGTTCTCAG 
 
3.10.   Cytokine Quantification 
 Culture supernatants were collected 24 hr after LPS stimulation, centrifuged at 
1700 rpm for 10 min at 4oC to remove cells and debris, and immediately frozen at -80o C 
for future cytokine and chemokine quantification.  Supernatants were thawed on ice and 




IL-6, IL-8, IL-10, IL-12p70, IFN-γ, TNF-α, RANTES, MCP-1, and MIP-1β (BioRad 
Laboratories, Hercules, CA).  For siRNA experiments, supernatants were analyzed with 
enzyme-linked immunosorbent assay (ELISA) kits for IL-10 (R&D Systems, 
Minneapolis, MD) and IL-12p70 (Enzo Life Science, Farmingdale, NY).  All samples 
and standards were run in duplicate and analyzed using the LUMINEX 200 (LUMINEX, 
Austin TX), or the BioTek EL800 (BioTek, Winooski, VT).  
 
3.11.   Statistical Analysis 
 Student’s t-tests (paired and unpaired) were used for statistical comparisons 
between groups, with p-values < 0.05 considered statistically significant.  Differential 
gene expression was considered statistically significant with a ≥ 2.5-fold change and a p-















4.1.   Figure 1 
 
 
Figure 1:  GILZ expression was rapidly down-regulated as monocytes differentiated 
into immature MoDCs, and up-regulated after exposure to dexamethasone.   
Total RNA was isolated from MoDCs.  A.) GILZ mRNA expression in CD11c+ MoDCs 
is presented as a fold change relative to freshly isolated monocytes.  B.) Median 
fluorescence intensities for intracellular markers (GILZ, CD83) and cell surface markers 




IL-4.  C.) GILZ mRNA expression in CD11c+ MoDCs after 24 hr is presented as a fold 
change relative to MoDCs receiving no dexamethasone.  D.) GILZ mRNA expression in 
CD11c+ MoDCs after 24 hr is presented as a fold change relative to untreated MoDCs.  
E.) GILZ mRNA expression in CD11c+ MoDCs is presented as a fold change relative to 
untreated MoDCs.  All data are expressed as mean ± standard deviation for a minimum of 
3 independent experiments.  For differential gene expression, a ≥ 2.5-fold change was 
chosen as the lower limit for considering statistically significant gene induction.  *p < 




GILZ expression was rapidly down-regulated as monocytes differentiated into 
immature MoDCs 
 
 Freshly isolated CD14+ monocytes expressed GILZ at high levels, but rapidly 
down-regulated GILZ expression by more than 99% as they differentiated into immature 
MoDCs in the presence of GM-CSF and IL-4 (Figure 1A, p < 0.001).  Expression of 
GILZ remained low in immature MoDCs for at least 72 hr in culture with no additional 
cytokines added.  The reduction in GILZ mRNA was confirmed by a 61% decrease in 
intracellular GILZ protein level, as assessed by flow cytometric staining (Figure 1B, p < 
0.01).  Down-regulation of GILZ mRNA and protein level was correlated with reduced 
expression of CD14, a monocyte-specific marker (89) (Figure 1B, p < 0.01), and 
increased expression of cytoplasmic CD83, a marker of immature MoDCs (90) (Figure 
1B, p < 0.01).  HLA-DR expression also increased after 36 hr of culture, with the median 
fluorescent intensity (MFI) increasing from 22.8 to 149.7 (p < 0.01), and the percentage 
of CD11c+ cells displaying a HLA-DR+/cytoplasmic CD83+ phenotype increasing from 
15.0 ± 11.6% to 90.8 ± 5.5% (p < 0.01).  Importantly, MoDCs remained phenotypically 
immature after 36 hr of culture, with a statistically insignificant change in expression of 




 As previously reported (59), dexamethasone induced the expression of GILZ in 
immature MoDCs in a dose-dependent fashion, starting at a dexamethasone concentration 
of 10 nM (Figure 1C, p < 0.05).  Treatment with 100 nM dexamethasone for 24 hr was 
selected as the positive control for inducing GILZ expression in MoDCs for all future 
experiments (now referred to as Dex-DCs).  In addition, after a single dose of 100 nM 
dexamethasone, GILZ was up-regulated 3.9-fold above untreated MoDCs for at least 72 
hr in culture, reflecting temporal stability of GILZ up-regulation (Figure 1F, p < 0.05).  
This observation enabled further experiments to operate on 48 hr time scales with a single 


















4.2.   Figure 2 
 
 
Figure 2: Immature MoDCs treated with 8-MOP plus UVA light up-regulated 
GILZ in a dose-dependent fashion and acquired a tolerogenic phenotype. 
Total RNA was isolated from MoDCs treated with PUVA.  A.) GILZ mRNA expression 
is presented as a function of the 8-MOP concentration at UVA light doses of 1 J/cm2 and 
2 J/cm2.  GILZ mRNA expression in CD11c+ MoDCs 24 hr after PUVA treatment is 
presented as a fold change relative to MoDCs receiving no 8-MOP.  B.) GILZ mRNA 
expression is presented as a function of the 8-MOP concentration multiplied by the UVA 
light dose.  GILZ mRNA expression in CD11c+ MoDCs 24 hr after PUVA treatment is 
presented as a fold change relative to MoDCs receiving no PUVA.  Relative fluorescence 
intensities for membrane expression of C.) HLA-DR and CD83, and D.) CD80 and 
CD86, are presented as a function of the 8-MOP concentration (0 to 200 ng/mL) 
multiplied by the UVA light dose (1 or 2 J/cm2), 24 hr after PUVA treatment in CD11c+-
gated MoDCs.  Untreated MoDCs served as reference controls.  All data represent mean 
± standard deviation for at least 4 independent experiments.  For differential gene 
expression, a ≥ 2.5-fold change was chosen as the lower limit for considering statistically 







4.3.   Table 1 
 
 
Table 1:  8-MOP plus UVA light induced a tolerogenic phenotype in immature 
MoDCs in a PUVA dose-dependent fashion. 
Individual relative fluorescence intensities for membrane expression of CD80, CD86, 
CD83 and HLA-DR are presented as a function of the 8-MOP concentration (0 to 200 
ng/mL) at both 1 and 2 J/cm2 UVA light in CD11c+-gated MoDCs.  Untreated MoDCs 
served as reference controls.  All data represent mean ± standard deviation for at least 4 
independent experiments.  Boxes shaded in dark grey indicate statistically significant 




The combination of 8-MOP and UVA light directly induced GILZ expression and 
established a tolerogenic phenotype in MoDCs  
  
  We next examined if PUVA has a direct effect on GILZ expression in immature 
MoDCs.  Treatment with 100 ng/mL 8-MOP or 1 J/cm2 UVA light alone did not 
significantly change GILZ expression (Figure 1E, p > 0.05).  However, when MoDCs 
were treated with the combination of 100 ng/mL 8-MOP and 1 J/cm2 UVA light (now 
referred to as PUVA-DCs), GILZ expression increased 5.5-fold in comparison to MoDCs 
receiving no PUVA treatment (Figure 1E, p < 0.05).  The induction of GILZ in PUVA-




treatment with a 4.3-fold change above untreated MoDCs, and remaining significantly 
elevated, above a 3-fold change, for 72 hr in culture (Figure 1F, p < 0.05).  In contrast, 
the induction of GILZ in Dex-DCs peaked in as little as 2 hr after dexamethasone 
treatment with an 8.7-fold change above untreated MoDCs, and remained significantly 
elevated for 72 hr in culture (Figure 1F, p < 0.05).  The percentage of apoptotic cells did 
not differ after treatment with 100 ng/mL 8-MOP or 1 J/cm2 UVA light, as compared to 
untreated MoDCs (data not shown).  There was also no significant difference in the total 
number of cells recovered from any group, and greater than 90% of CD11c+ MoDCs 
remained viable 24 hr after treatment with 100 ng/mL 8-MOP, 1 J/cm2 UVA light, or the 
combination of both (data not shown). 
 After establishing that PUVA induces GILZ expression, we examined if there was 
an 8-MOP or UVA light dose-dependent effect on GILZ induction.  MoDCs treated with 
1 J/cm2 UVA light up-regulated GILZ 2.9- and 4.4-fold higher than untreated MoDCs as 
the 8-MOP concentration reached therapeutic doses of 100 and 200 ng/mL respectively 
(Figure 2A, p < 0.01).  A similar dose-dependent phenomenon was observed with 2 
J/cm2 UVA light, starting at a lower 8-MOP dose of 50 ng/mL (Figure 2A, p < 0.01).    
 In vivo studies utilizing highly specific 8-MOP photo-adduct monoclonal 
antibodies in human lymphocytes revealed that the number of photo-adducts formed per 
one million base pairs is directly proportional to the product of the 8-MOP concentration 
and UVA light dose (91).  When examining GILZ expression as a function of the 8-MOP 
and UVA light product, a similar dose-dependent effect was observed.  GILZ was up-
regulated 3-fold above untreated MoDCs as the product of 8-MOP and UVA light 




(Figure 2B, p < 0.01).   Treatment with 0.5 J/cm2 UVA light had no significant effect on 
GILZ expression until the 8-MOP dose was greater than 200 ng/mL (data not shown).  
Treatment with 4 J/cm2 UVA light resulted in high levels of non-specific cell death post-
treatment, and the effects of this higher UVA light dose on GILZ expression could not be 
reliably determined (data not shown).   
 In dexamethasone-treated cultures, expression of GILZ truncates DC maturation 
and mediates the conversion to a tolerogenic phenotype (92).  In a similar fashion, the 
PUVA dose-dependent induction of GILZ was correlated with decreased cell surface 
expression of the maturation marker membrane CD83 (Figure 2C, p < 0.01), and the co-
stimulatory molecules CD80 and CD86 (Figure 2D, p < 0.01), in CD11c+-gated MoDCs.  
Down-regulation of these markers paralleled the induction of GILZ (see Figure 2B), 
beginning at an 8-MOP concentration of 100 ng/mL for UVA light doses of 1 and 2 
J/cm2.  As the product of 8-MOP and UVA light exceeded 100, the expression of CD83, 
CD80 and CD86 were reduced by 31%, 30% and 54% respectively (Figure 2C, 2D, p < 
0.01), and the expression of HLA-DR was increased by 38% (Figure 2C, 2D, p < 0.05).   
 These same trends were observed when examining the relative fluorescence 
intensities (RFIs) for each cell surface marker, at each particular dose of 8-MOP and 
UVA light in CD11c+-gated MoDCs.  As the 8-MOP concentration increased at both 1 
and 2 J/cm2 UVA light, the RFIs for CD80, CD86 and CD83 all steadily decreased, in a 
similar fashion as Dex-DCs (Table 1, p < 0.05).  Although the expression of HLA-DR 
increased at 100 ng/mL 8-MOP for both 1 and 2 J/cm2 UVA light, it dropped 




Greater than 90% (range 91.0-97.5%) of CD11c+ MoDCs were harvested from all 






























Figure 3:  MoDCs were relatively resistant to the apoptotic effects of 8-MOP plus 
UVA light. 
A.) Flow cytometry dot plots of CD11c+-gated MoDCs treated with UVA light doses of 1 
J/cm2 or 2 J/cm2, and increasing concentrations of 8-MOP, are shown for 1 representative 
experiment of 4.  The percentages of CD11c+ cells displaying Annexin-V+/7-AAD- (early 
apoptotic) or Annexin-V+/7-AAD+ (late apoptotic) phenotypes are indicated.  The 
percentages of B.) Annexin-V+/7-AAD- (early apoptotic) and C.) Annexin-V+/7-AAD+ 
(late apoptotic) phenotypes are quantified and presented as a function of the 8-MOP 
concentration and UVA dose.  Untreated cells served as reference controls.  All data 
represent mean ± standard deviation for at least 4 independent experiments.  *p < 0.05, 











Figure 4:  MoDCs and lymphocytes differed in their susceptibility to the apoptotic 
effects of 8-MOP plus UVA light. 
A.) Flow cytometry dot plots of CD11c+-gated MoDCs and CD3+-gated lymphocytes 
treated with a UVA light dose of 1 J/cm2, and increasing concentrations of 8-MOP, are 
shown for 1 representative experiment of 3.  The percentages of CD11c+ MoDCs 
displaying an Annexin-V+/7-AAD- (early apoptotic) or Annexin-V+/7-AAD+ (late 
apoptotic) phenotype are indicated at 0, 2, 8 and 24 hr.  The percentages of B.) CD11c+ 
MoDCs and C.) CD3+ lymphocytes expressing early and late apoptotic cell markers were 
quantified 24 hr after treatment with 100 ng/mL 8-MOP and 1 J/cm2 UVA light.  
Untreated MoDCs and lymphocytes served as reference controls.  All data represent 
mean ± standard deviation for at least 3 independent experiments.  *p < 0.05, compared 





Lymphocytes were particularly susceptible, whereas MoDCs were relatively 
resistant, to the apoptotic effects of PUVA 
 
 There is a lack of consensus in the literature regarding the apoptotic effects of 
PUVA treatment on monocytes and DCs, with studies showing both a resistance (12, 21-
23), and sensitivity (24-26), to apoptosis.  The relative resistance of MoDCs to the 
apoptotic effects of PUVA can be directly observed on flow cytometry dot plots from 1 
representative experiment of 4 (Figure 3A).  The percentage of early apoptotic (Annexin-
V+/7-AAD-) CD11c+-gated MoDCs was minimally higher when treated with 2 J/cm2 as 
compared to 1 J/cm2 UVA light, across the range of 8-MOP concentrations tested (0 to 
200 ng/mL) (Figure 3A, p > 0.05).  Of note, there was a statistically significant increase 
in the percentage of early apoptotic CD11c+-gated MoDCs when treated with 2 J/cm2 
UVA light and 200 ng/mL 8-MOP, as compared to untreated MoDCs (Figure 3A, 3B, p 
< 0.05).  Nevertheless, apart from this isolated PUVA dose, the percentage of early 
apoptotic MoDCs remained below 25% (range 3.4-20.2%) over the range of 8-MOP and 
UVA light doses examined (Figure 3B, p > 0.05).   
 The percentage of late apoptotic (Annexin-V+/7-AAD+) CD11c+-gated MoDCs 
also remained low (range 6.3-15.2%), and statistically not different than untreated 
MoDCs, at both 1 J/cm2 and 2 J/cm2 UVA light for all concentrations of 8-MOP tested 
(Figure 3C, p > 0.05).  Moreover, greater than 90% CD11c+ MoDCs (range 91.0-97.5%) 
were harvested after PUVA treatment from all groups treated with 1 or 2 J/cm2 UVA 
light. 
  In comparison to MoDCs, CD3+-gated lymphocytes displayed phosphatidylserine 
on their cell surface as early as 2 hr after treatment with 1 J/cm2 UVA light and 100 




representative experiment of 3, 2 hr after treatment with 1 J/cm2 UVA light and 100 
ng/mL 8-MOP, the percentage of early apoptotic CD3+-gated lymphocytes increased 
from 7.5% to 21.1% (Figure 4A).  Moreover, the percentage of early and late apoptotic 
CD3+-gated lymphocytes further increased at both 8 and 24 hr (Figure 4A).  In 
comparison, there was no significant increase in the percentage of early or late apoptotic 
CD11c+-gated MoDCs after treatment with the same dose of 8-MOP and UVA light at 2, 
8 or 24 hr (Figure 4A).   
 Figures 4B and 4C quantify the striking difference in susceptibility of MoDCs and 
lymphocytes to an identical 8-MOP and UVA light dose.  While there were no 
differences observed in the percentages of early or late apoptotic CD11c+-gated MoDCs 
24 hr after treatment with 100 ng/mL 8-MOP and 1 J/cm2 UVA light (Figure 4B, p > 
0.05), there was a large increase in the percentage of early and late apoptotic lymphocytes 
24 hr after PUVA treatment (Figure 4C, p < 0.05).  The percentage of early apoptotic 
lymphocytes increased from 6.6% in untreated lymphocytes to 44.3% in PUVA-treated 
lymphocytes, and the percentage of late apoptotic lymphocytes increased from 4.5% to 
33.7% (Figure 4C, p < 0.05).  Given that 64.3 ± 3.2% (p < 0.001) of CD3+-gated 
lymphocytes displayed phosphatidylserine on their cell surface and were apoptotic 24 hr 
after PUVA treatment, PUVA-treated lymphocytes are subsequently referred to as 












Figure 5:  Immature MoDCs exposed to apoptotic lymphocytes up-regulated GILZ 
and were resistant to full maturation with LPS.   
A.) GILZ mRNA expression in CD11c+ MoDCs 24 hr after co-culture is presented as a 
fold change relative to untreated MoDCs that were cultured alone.  MoDCs were co-
cultured in ratios of five and ten apoptotic lymphocytes to one untreated MoDC.  B.) 




change relative to untreated MoDCs that were cultured alone.  C.) Relative fluorescence 
intensity of GILZ 24 hr after co-culture.  Relative fluorescence intensities post- to pre-
LPS stimulation for D.) CD80 and CD86, and E.) HLA-DR and CD83, were calculated 
as follows:  (MFItreated after LPS – MFItreated before LPS) / (MFIuntreated after LPS – MFIuntreated before 
LPS).  Data represent mean ± standard deviation for at least 4 independent experiments.   
For differential gene expression, a ≥ 2.5-fold change was chosen as the lower limit for 
considering statistically significant gene induction.  *p < 0.05, **p < 0.01, ***p < 0.001, 
compared to the untreated MoDC group, unless noted otherwise. 
 
 
MoDCs exposed to apoptotic lymphocytes increased expression of GILZ and were 
resistant to full maturation after LPS stimulation 
 
 To dissect the direct effects of PUVA on MoDCs, and the indirect effects of 
PUVA through the generation of ApoL, immature MoDCs were co-cultured for 24 hr 
with increasing numbers of ApoL.  Exposure of MoDCs to ApoL induced GILZ 
expression in an ApoL dose-dependent fashion, with GILZ expressed higher in MoDCs 
co-cultured in a ten to one ratio of ApoL to MoDCs as compared to a five to one ratio 
(4.4-fold compared to 2.8-fold higher than untreated MoDCs, respectively) (Figure 5A, p 
< 0.01).  As a positive control, dexamethasone induced GILZ expression 4.2-fold above 
untreated MoDCs in this particular set of experiments (Figure 5A, p < 0.01).  
  In addition, PUVA-DCs co-cultured with ApoL expressed GILZ at higher levels 
than PUVA-DCs cultured alone (6.7-fold compared to 2.8-fold higher than untreated 
MoDCs, respectively) (Figure 5B, p < 0.05).  PUVA-DCs exposed to ApoL also 
expressed GILZ at higher levels than did untreated MoDCs exposed to ApoL (6.7-fold 
compared to 3.6-fold higher than untreated MoDCs, respectively) (Figure 5B, p < 0.01).  
Increased GILZ mRNA production was associated with at least a 1.5-fold increase (range 
1.56-2.23) in the intracellular level of GILZ protein (Figure 5C, p < 0.001).  The 
induction of GILZ was not related to an increase in the number of early or late apoptotic 




apoptotic (range 6.3-11.5%) CD11c+ MoDCs in all groups demonstrating induction of 
GILZ (p > 0.05, as compared to untreated MoDCs).   
 Immature MoDCs exposed to LPS rapidly mature and increase membrane 
expression of HLA-DR, CD83, CD80 and CD86 (93).  MoDCs expressing GILZ greater 
than 2.5-fold above untreated MoDCs were resistant to full maturation by the TLR4 
ligand LPS, and acquired a semi-mature, tolerogenic phenotype.  LPS stimulation 
increased CD80 expression in MoDCs up-regulating GILZ to only 50% (range 48-57%) 
of the levels seen after LPS stimulation in untreated MoDCs (Figure 5D, p < 0.05), and 
LPS stimulation increased CD86 expression to only 45% (range 42-47%) of untreated 
MoDCs (Figure 5D, p < 0.01).  Similar results were obtained for CD83 (range 47-65%) 
and HLA-DR (range 23-57%), as compared to untreated MoDCs after LPS stimulation 
(Figure 5E, p < 0.05).  The reduction in cell surface marker expression was confirmed at 
the mRNA level for CD80 and CD86, as assessed by qRT-PCR.  MoDCs up-regulating 
GILZ expressed 6% of the CD80 mRNA transcript level of untreated MoDCs (range 4.5-
7.5%, p < 0.05) and expressed 50% of the CD86 mRNA transcript level of untreated 
MoDCs (range 12.4-85.1%, p < 0.05).  MoDCs not stimulated with LPS served as 
negative controls, and demonstrated baseline expression levels for all cell surface 
markers, and also had low transcript levels for both CD80 and CD86 mRNA (data not 



















Figure 6:  MoDCs up-regulating GILZ at high levels increased IL-10 production, 
and decreased production of various pro-inflammatory cytokines and chemokines.  
MoDCs from cultures described in Figure 5 were stimulated with LPS, and after 24 hr 
culture supernatants were harvested for cytokine quantification by magnetic bead 
multiplex immunoassays for A.) IL-10, and the pro-inflammatory cytokines B.) IL-12p70 
and IFN-γ, and C.) IL-6 and TNF-α.  The same analysis was performed for the pro-
inflammatory chemokines D.) IL-8, and E.) MCP-1, MIP-1β and RANTES.  Data are 
presented as mean ± standard deviation for 3 independent experiments.  *p < 0.05 






















Figure 7: siRNA-mediated knockdown of GILZ abolished the tolerogenic cytokine 
profile, as evidenced by reduced IL-10 production and increased IL-12 production. 
MoDCs were transfected with GILZ or scramble siRNA, and cultured as described in 
Figure 5.  A.) GILZ mRNA expression in CD11c+ MoDCs transfected with GILZ or 
scramble siRNA is presented as a fold change compared to non-transfected, untreated 
MoDCs that were cultured alone. * ≥ 2.5-fold change and p < 0.05, compared to 
identically treated MoDCs not transfected with siRNA.  Quantification of B.) IL-10 and 
C.) IL-12p70 protein levels in culture supernatants 24 hr after LPS stimulation.  Data 
represent mean ± standard deviation for 3 independent experiments.  *p < 0.05, compared 



















Table 2:  MoDCs expressing GILZ at high levels demonstrated an increased IL-10 
to IL-12 ratio characteristic of tolerogenic DCs, and siRNA-mediated knockdown of 
GILZ reduced the IL-10 to IL-12 ratio. 
GILZ mRNA expression in CD11c+ MoDCs is presented as a fold change relative to 
untreated MoDCs that were cultured alone.  Individual IL-10 and IL-12 levels are 
presented, with a calculation of the IL-10 to IL-12 ratio for each group.  Data represent 
mean ± standard deviation for 3 independent experiments.  Shaded boxes highlight the 




MoDCs expressing high levels of GILZ displayed a tolerogenic cytokine profile, and 
siRNA-mediated knockdown of GILZ reduced the IL-10 to IL-12 ratio 
 
 Tolerogenic DCs are characterized by increased production of 
immunosuppressive cytokines and decreased production of pro-inflammatory cytokines 
and chemokines (36, 40-42).  To analyze the functionality of MoDCs expressing GILZ at 
high levels, supernatants were harvested from the co-cultures described in Figure 5B.  
Dex-DCs expressed GILZ 4.29-fold above untreated MoDCs (see Figure 5B, p < 0.01), 
and in comparison to untreated MoDCs, increased production of the immunosuppressive 
cytokine IL-10 (Figure 6A, p < 0.05).  In addition, Dex-DCs decreased production of the 




(Figure 6C, p < 0.05), and chemokines IL-8 (Figure 6D, p < 0.05), and MCP-1 and 
RANTES (Figure 6E, p < 0.05).  Dex-DCs did not, however, significantly decrease 
production of the chemokine MIP-1β (Figure 6E, p > 0.05). 
 PUVA-DCs expressed GILZ 2.78-fold above untreated MoDCs (see Figure 5B, p 
< 0.01), and in comparison to untreated MoDCs, increased production of IL-10 (Figure 
6A, p < 0.05).  PUVA-DCs also decreased production of IL-12p70, IL-6, IL-8, MCP-1, 
MIP-1β and RANTES (Figure 6B-6E, p < 0.05), but not TNF-α or IFN-γ (Figure 6B, 
6C, p > 0.05).  As previously noted, both PUVA-DCs and untreated MoDCs, when co-
cultured with ApoL, expressed GILZ at higher levels that PUVA-DCs cultured alone 
(3.6- and 6.7-fold higher, respectively) (see Figure 5B, p < 0.01).  In comparison to 
untreated MoDCs, these two groups both increased production of IL-10 (Figure 6A, p < 
0.05), and decreased production of the pro-inflammatory cytokines IL-12p70, IFN-γ, IL-6 
and TNF-α (Figure 6B, 6C, p < 0.05) and chemokines IL-8, MCP-1, MIP-1β and 
RANTES (Figure 6D, 6E, p < 0.05).  
 Cytokine levels were also analyzed at the RNA level for IL-10, IL-12, TNF-α and 
TGF-β, as assessed by qRT-PCR.  MoDCs that significantly up-regulated GILZ 2.5-fold 
above untreated MoDCs also up-regulated IL-10 mRNA transcripts to levels 8-fold 
greater than untreated MoDCs (range 5.5-11.8 fold higher, p < 0.01).  Moreover, these 
MoDCs down-regulated IL-12 mRNA transcripts to levels 1.7-fold lower than MoDCs 
(range 1.1-3.2 fold lower, p < 0.05), and down-regulated TNF-α mRNA transcripts to 
levels 1.4-fold lower than MoDCs (range 1.1-2.0 fold lower, p > 0.05).  In addition, TGF-
β mRNA was up-regulated in PUVA-DCs 3.4-fold above untreated MoDCs (range 2.2-




regulated 3.0-fold above untreated MoDCs (range 2.9-3.0 fold higher, p < 0.05).  In 
untreated MoDCs exposed to ApoL, TGF-β was marginally up-regulated only 2.1-fold 
above untreated MoDCs (range 1.2-3.0 fold higher, p > 0.05), and TGF-β mRNA 
transcripts were actually lower in Dex-DCs (0.8-fold lower in comparison to untreated 
MoDCs) (range 0.8-0.9 fold lower, p > 0.05).  Of note, TGF-β was not included in the 
multiplex cytokine analysis and therefore was only analyzed at the mRNA level. 
 To assess whether the induction of GILZ was mediating the observed tolerogenic 
cytokine profile, MoDCs were transfected with GILZ specific-siRNA to transiently 
knockdown GILZ expression.  Transfection with GILZ siRNA reduced GILZ expression 
in MoDCs by 65% (range 57-69%, of non-transfected MoDCs) (Figure 7A, p < 0.05).  
Transfection with scramble siRNA did not significantly change GILZ expression (range 
86-112% of non-transfected MoDCs) (Figure 7A, p > 0.05).  There was no significant 
difference in the number of cells recovered from any group transfected with siRNA as 
compared to non-transfected groups (data not shown, p > 0.05).  MoDCs up-regulating 
GILZ 2.5-fold higher than untreated MoDCs, in both the non-transfected and scramble 
siRNA groups, produced higher levels of IL-10 (Figure 7B, p < 0.05).  Transient 
knockdown of GILZ reduced IL-10 production by 39% (range 34-48%) (Figure 7B, p < 
0.05).  MoDCs up-regulating GILZ 2.5-fold higher than untreated MoDCs in both the 
non-transfected and scramble siRNA groups also produced lower levels of IL-12p70 
(Figure 7C, p < 0.05).  Transient knockdown of GILZ increased IL-12p70 production by 
188% (range 149-214%) (Figure 7C, p < 0.05).  Treatment with scramble siRNA had no 
appreciable effect on the production of either IL-10 or IL-12p70 (Figure 7B, 7C, p > 




 The ratio of IL-10 to IL-12 production is a useful indicator of tolerogenicity, and 
tolerogenic DCs are characterized by an increased IL-10 to IL-12 ratio (36, 40-42).  The 
IL-10 to IL-12 ratio increased from 5.0 in untreated MoDCs to 15.3 in Dex-DCs (Table 
2).  Similarly, the IL-10 to IL-12 ratio increased to 8.4 in PUVA-DCs, increased to 18.1 
in untreated MoDCs exposed to ApoL, and increased to 28.4 in PUVA-DCs exposed to 
ApoL (Table 2).   
 Transient knockdown of GILZ with siRNA reduced the IL-10 to IL-12 ratio that 
had been elevated following GILZ induction.  The IL-10 to IL-12 ratio decreased from 
15.3 to 3.9 in siRNA transfected Dex-DCs (Table 2).  Similarly, in siRNA transfected 
PUVA-DCs, the ratio decreased from 8.4 to 2.9, in siRNA transfected untreated MoDCs 
exposed to ApoL, the ratio decreased from 18.1 to 7.8, and finally in siRNA transfected 





















5.1.   Summary of Results 
 
 This study demonstrates that PUVA acts directly on MoDCs, and indirectly 
through the generation of ApoL, to induce expression of GILZ.  MoDCs up-regulating 
GILZ displayed a tolerogenic phenotype, characterized by moderate expression of the 
MHC-class II molecule HLA-DR, low expression of the co-stimulatory molecules CD80 
and CD86, and low expression of the maturation marker CD83.  Moreover, MoDCs up-
regulating GILZ were resistant to full maturation by the TLR4 ligand LPS, indicating that 
they were in a tolerogenic, semi-mature state, unable to mature and respond to classic 
immunogenic stimuli. 
 In addition, MoDCs treated with PUVA, or exposed to lymphocytes rendered 
apoptotic by PUVA, were polarized towards a tolerogenic cytokine profile, characterized 
by increased IL-10 production and decreased production of pro-inflammatory cytokines, 
including IL-12, IFN-γ, IL-6 and TNF-α, and chemokines, including IL-8, MCP-1, MIP-
1β, and RANTES.  GILZ was necessary for the conversion to this tolerogenic cytokine 
profile, as demonstrated by a reduction in the IL-10 to IL-12 ratio after siRNA-mediated 
transient knockdown of GILZ.  PUVA and apoptotic cells can now be included in the list 
of immunosuppressive stimuli - including glucocorticoids, IL-10 and TGF-β - all sharing 








5.2.   Direct Effects of PUVA 
 
 The molecular pathways mediating PUVA’s direct induction of GILZ are 
presently unknown, but may be related to DNA damage, protein modifications, or 
cellular stress.  IL-10 levels were also elevated in PUVA-treated cultures, indicating that 
autocrine or paracrine IL-10 signaling could have been the primary event inducing GILZ 
expression (73).  However, this is less likely given that the measured IL-10 concentration 
was 350 times lower than that used to induce moderate GILZ expression in prior studies 
(59).  
 While 8-MOP is biologically inert in the absence of UVA light energy, UV 
radiation is immunosuppressive (1, 3), and activates numerous transcription factors, 
including the immediate early genes c-fos, c-jun, and c-myc (94) .  Moreover, 
transcription factor induction is observed even in DNA repair-deficient cells (94), 
indicating that photo-adduct repair and processing are not required for gene induction.  
PUVA itself also alters gene expression in mouse keratinocytes (95), and generates bulky 
DNA-protein cross-links (96), reactive oxygen species (97, 98), and lipid modifications 
(99, 100), all of which may be able to induce gene expression.  Given the relative 
resistance of MoDCs to apoptosis, sub-lethal DNA damage and generalized cellular stress 
may be capable of inducing GILZ and generating tolerogenic DCs.  Interestingly, IL-2 
growth factor deprivation induces GILZ expression in T-lymphocytes and protects them 
from IL-2 withdrawal-induced apoptosis (101).  PUVA may induce GILZ expression in a 
similar fashion, protecting MoDCs from PUVA-induced apoptosis. 
 Multiple studies link cellular stress with GILZ induction.  Firstly, rat 




fashion (102).  Secondly, caspase-8, linked to the immediate pre-programmed apoptotic 
pathway induced by PUVA (16, 17), protects GILZ from degradation by facilitating its 
binding to the small ubiquitin-like modifier 1 (SUMO-1) (103).  SUMO-1 is covalently 
attached to proteins during post-translational modifications, and is involved in many 
cellular processes, including apoptosis and the response to stress (103).  The presence of 
SUMO binding sites on the GILZ protein suggests a close relationship between GILZ 
induction, cellular stress and apoptosis (103).  Thirdly, a recent report suggested that 
treatment of mouse bone marrow derived DCs with thermal stress in the presence of 
carvacrol, a molecule with anti-inflammatory properties, could induce functionally 
tolerogenic DCs (104).  Fourthly, GILZ has even been shown to be an alcohol-responsive 
gene, becoming up-regulated in response to ethanol in a dose-dependent manner (105).  
Finally, exposure to certain microbial products, including C. difficile toxin B and Y. 
enterocolitica virulence factor YopT, induce GILZ expression (106).  The notion that 
cellular stress may induce a default tolerogenic pathway of DC differentiation has not 
been systematically explored to date.  However, given the importance of maintaining 
peripheral tolerance to self-antigens exposed during tissue damage in times of 
inflammation and infection (34-36), the idea that a tolerogenic differentiation program 
may become activated in a subset of DCs during stressful environmental conditions 
warrants further investigation. 
 The product of the 8-MOP and UVA light dose is directly proportional to the 
number of photo-adducts formed per one million base pairs (91).  A direct role for protein 
and/or DNA photo-adduct formation contributing towards GILZ induction is supported 




2B).  It is interesting to note that the induction of GILZ, and down-regulation of CD80, 
CD86 and CD83, only occurred as the product of 8-MOP and UVA light reached 
therapeutic levels, namely between 100 and 200 (see Figure 2C, 2D).  Doses of 8-MOP 
and UVA light used during ECP vary between treatment centers, but generally range 
from 1 to 2 J/cm2 of UVA light and from 100 to 200 ng/mL of 8-MOP (7-10).  Down-
regulation of these markers was likely not due to the non-specific global suppression of 
all cell surface marker expression, as the expression level of HLA-DR increased at 
identical PUVA doses.  In support of these data, a prior study also noted increased 
antigen uptake and HLA-DR expression in PUVA-treated MoDCs (53), and also 
enhanced MHC class I synthesis after low-dose PUVA treatment (98). 
 
5.3.   Apoptotic Effects of PUVA 
 In support of previously published studies (12, 21-23), MoDCs were relatively 
resistant to the apoptotic effects of PUVA.  The discrepancy between these data, and 
other reports suggesting a susceptibility of MoDCs to apoptosis (24-26), may stem from 
variations in the PUVA dose used for treatment.  For example, Holtick et al. reported a 
susceptibility of MoDC to apoptosis, but utilized both a high 8-MOP concentration (300 
ng/mL) and UVA light dose (2 J/cm2) (25).  This 8-MOP and UVA light product, 
proportional to the extent of DNA damage, is approximately twice the therapeutic dose 
(7, 25).  Likewise, Yoo et al. reported that MoDC apoptosis was observed with 8-MOP 
administration alone, at doses greater than 300 ng/mL (13), and with UVA light alone, at 
doses greater than 2 J/cm2 (13), suggesting that very high doses of either 8-MOP or UVA 




 In this present study, high doses of PUVA only minimally increased the 
percentage of early apoptotic MoDCs.  However, after treatment with a supra-therapeutic 
dose (2 J/cm2 UVA light and 200 ng/mL 8-MOP), the percentage of early apoptotic 
MoDCs significantly increased (see Figure 3).  The transcriptional and phenotypic 
changes observed at this high PUVA dose were likely non-specific, given a marked 
decrease in the RFIs for all cell surface markers, including HLA-DR (see table 1).  
Importantly though, no therapeutic PUVA dose used in this study increased the 
percentage of late apoptotic MoDCs above the levels observed with untreated MoDCs, 
indicating that rapid MoDC death is likely not occurring during or after ECP.    
 The previously documented exquisite sensitivity of lymphocytes to the apoptotic 
effects of PUVA was confirmed in this study (12-14).  Over 60% of lymphocytes 
displayed phosphatidylserine on their cell surface 24 hr after PUVA treatment, and 
between 70% and 90% of lymphocytes entered a late stage of apoptosis 48 hr after 
treatment.  In fact, as early as 2 hr after PUVA treatment, 21% of lymphocytes displayed 
phosphatidylserine, illustrating the activation of an immediate pre-programmed apoptotic 
pathway (16, 17).   
 
5.4.   Indirect Effects of PUVA 
 The transcription factor NF-κB is a key regulator of many genes associated with 
DC immunogenicity, and many inflammatory stimuli, such as LPS, TNF-α, and IL-1, 
induce DC maturation through activation of the NF-κB pathway (107).  Therefore, it is 
not surprising that many immunosuppressive stimuli act by inhibiting NF-κB, and GILZ 




69).  In addition, the exposure of DCs to apoptotic cells has been shown to inhibit NF-κB 
(108), leading to a truncation in DC maturation and polarization towards a tolerogenic 
functional state (109).  This present study implicates GILZ as the downstream molecular 
mediator transmitting the immunosuppressive effects of apoptotic cells, ultimately 
resulting in NF-κB inhibition.  MoDCs exposed to ApoL up-regulated GILZ in an 
apoptotic cell dose-dependent manner, and acquired a tolerogenic phenotype and 
function.  The tolerogenic functional profile of these cells was diminished after transient  
knockdown of GILZ with siRNA. 
 The immunosuppressive elements associated with apoptotic cells have not been 
fully elucidated, but likely involve unique molecular characteristics of the apoptotic cell, 
the production of tolerogenic factors, the kinetics of cell death, and the nature of the 
apoptotic-inducing stimulus (110).  Apoptotic lymphocytes display phosphatidylserine on 
their surface soon after apoptosis is initiated (83), and this process triggers recognition 
and removal by APCs (82).  Receptors involved in the recognition and internalization of 
apoptotic bodies include phosphatidylserine receptors (TAM receptors) (84), the 
thrombospondin receptor (CD36) (78, 79), the vitronectine receptor (αVβ3 integrin) (74), 
and other scavenger receptors (78).  Notably, both phosphatidylserine (79), and anti-
CD36 (83), are capable of transmitting immunosuppressive signals from apoptotic cells.  
This suggests that the exposure of phosphatidylserine and other molecules recognized by 
scavenger receptors may comprise the bulk of these signals.  Recently, membrane blebs 
containing high levels of phosphatidylserine were observed to originate from apoptotic 
lymphocytes after PUVA treatment,, and these membrane blebs contained an 




recognition and internalization of membrane blebs constituted the major 
immunosuppressive signal from apoptotic lymphocytes and induced GILZ expression in 
this study.   
 In addition, lymphocytes release both IL-10 (112) and TGF-β (113) as they 
undergo controlled apoptosis, and UV-irradiated lymphocytes have also been observed to 
produce IL-10 (114).  It remains a possibility that GILZ induction may have resulted 
from IL-10 release by ApoL, with subsequent paracrine signaling within cell culture.  In 
contrast, rapid lymphocyte apoptosis, leading to secondary necrosis, results in the release 
of numerous DAMPs, including high-mobility group box-1 (HMGB-1), heat shock 
proteins, uric acid, and mammalian DNA, all of which are highly immunogenic (110).  
Thus the extent of cell death and the kinetics of apoptotic induction likely play a key role 
in determining which types of signals are transmitted (110).  Of interest, lymphocytes in 
this study exhibited widespread apoptotic death following PUVA exposure, but first 
entered through a distinct early apoptotic stage in which their cellular membranes were 
intact and DAMPs were presumably not released in significant quantities (see Figure 
4A).  Moreover, there was no indication of lymphocyte necrosis preceding apoptosis, 
providing additional circumstantial evidence that MoDCs were capable of processing 
these cells efficiently before they entered stages of late apoptosis. 
  An additional interesting hypothesis is that reactive oxygen species generated 
from PUVA exposure may modify HMGB-1 and other DAMPs, abolishing their intrinsic 
immunogenicity once released from the dying cell (110).  In support of this claim, 
Kazama et al. demonstrated that the induction of tolerance by apoptotic cells requires 




apoptotic pathway in lymphocytes involving caspase-3, -8, and -9 (15-17), apoptotic 
lymphocytes induced by PUVA may be uniquely conditioned to induce tolerance through 
the oxidation and neutralization of HMGB-1 (115).  A limitation of this present study is 
that only the exposure of MoDCs to ApoL was linked with GILZ induction.  A 
requirement for cell-contact between DCs and ApoL, or the contributions from 
internalization, release of IL-10 or DAMPs, and other signaling pathways were not fully 
investigated.  Additional studies will be required to elucidate precisely how cell-to-cell 
contact, IL-10 production by PUVA-treated cells, and the internalization of apoptotic 
bodies contribute to the induction of GILZ.   
 One intriguing possibility is that TAM receptor signaling may provide the missing 
link between cell surface recognition of apoptotic cells and GILZ induction.  TAM 
(Tyro3, Axl, Mer) receptors are a family of tyrosine kinases capable of transducing 
immunosuppressive signals from apoptotic cells (84, 116).  TAM receptors were 
originally demonstrated to inhibit TLR-induced inflammation in a tripartite model 
postulated by Rothlin et al. (117).  This model asserts that TLR ligation initially leads to 
the production of cytokines that promote inflammation and host defense (117).  In the 
second part of the model, these pro-inflammatory cytokines amplify the inflammatory 
response through feed-forward signaling (117).  In the final stage, these same cytokines 
induce TAM receptor activation as a negative feedback mechanism to inhibit the 
inflammatory response (117).  This system is postulated to enable the immune system to 
quickly launch an immunogenic, pro-inflammatory response that is ensured to be self-





 TAM receptors also have an important role in apoptotic cell homeostasis (84).  
TAM-deficient cells fail to properly internalize apoptotic cells and membranes (84), and 
autoimmune disease universally develops in TAM knockout mice, likely as a result of the 
aberrant clearance of apoptotic cells by APCs (116, 118).  Growth arrest-specific 6 
(GAS6) and protein S, two TAM receptor ligands produced by macrophages and DCs, 
bind phosphatidylserine and form a molecular bridge between the apoptotic cell 
displaying phosphatidylserine and the APC expressing TAM receptors (84, 117, 118).  
Phosphatidylserine also stabilizes the interaction between the TAM receptor and its 
ligands, preventing dissociation and ensuring strong and persistent down-stream 
intracellular signaling through the TAM receptor (84, 116-118).  In this model, 
phosphatidylserine is the only immunosuppressive stimuli carried by an apoptotic cell 
(84), and the internalization or clearance of apoptotic bodies would not be absolutely 
required for tolerance induction. 
 The net result of TAM receptor signaling is inhibition of the same pro-
inflammatory signaling pathways as GILZ, including NF-κB, MAPK and EKR-1/2 (84, 
117-119).  Specifically, signaling through Mer, a TAM receptor expressed on DCs, 
inhibits LPS-induced NF-κB activation and reduces IL-12 and TNF-α production (120, 
121).  Curiously both GILZ and TAM knockout mice have a similar phenotype in the 
testes, characterized by defects in the phagocytic clearance of apoptotic cells, a complete 
loss of the germ cell lineage, and male sterility (59, 84).  Given the central importance of 
TAM receptors in clearing apoptotic bodies (84, 119), transmitting their 




pathways after TLR-ligation (116, 117), the possibility that TAM receptor signaling leads 
to the downstream induction of GILZ should be further investigated.    
 An unanswered question from this study is whether interactions between 
apoptotic MoDCs and viable MoDCs may have been responsible for the induction of 
GILZ observed in PUVA-DC cultures.  PUVA-DCs were cultured at low cell density and 
were relatively adherent to the plastic culture well.  Nevertheless, the possibility remains 
that a small percentage of apoptotic MoDCs in culture may have generated membrane 
blebs with high levels of phosphatidylserine (111), capable of diffusing and bridging the 
distance between individual cells to transmit immunosuppressive signals. 
 Of note, the time course for GILZ induction differed greatly between Dex-DCs 
and PUVA-DCs (see Figure 1E).  Dexamethasone induced maximum GILZ expression 
within 2 hr of PUVA treatment, and the expression remained elevated for at least 72 hr in 
culture.  This observation is consistent with the known pharmacokinetics of 
glucocorticoids.  Dexamethasone, like all glucocorticoids, is lipid soluble and rapidly 
diffuses into the cytoplasm of cells where it associates with the cytosolic glucocorticoid-
receptor (70, 71).  This complex then travels to the nucleus and binds to the 
glucocorticoid-response elements upstream of the GILZ promoter, thereby inducing 
GILZ mRNA transcription (70, 71).  In contrast, PUVA-DCs did not demonstrate 
significant up-regulation of GILZ until 8 hr after PUVA treatment, and the maximum 
expression level occurred only after 24 hr.  This suggests a fundamental difference 
between dexamethasone and PUVA treatment in regards to the mechanism leading to 
GILZ induction.  The cellular events mediating the direct effects of PUVA on MoDCs, 




before GILZ mRNA is ultimately transcribed.  Alternatively, this observation may be 
demonstrating that MoDCs must first enter the apoptotic pathway, and then be 
recognized and internalized by viable MoDCs, before the induction of GILZ occurs.  
 Nevertheless, GILZ was induced at high levels in MoDCs treated with PUVA 
doses that did not result in an increase in the percentage of early apoptotic MoDCs above 
the level observed in untreated cultures (see Figure 2B).  However, if the 
immunosuppressive signals delivered by an apoptotic DC and an ApoL are not 
equivalent, then it may be possible for far fewer apoptotic DCs to mediate a tolerogenic 
effect.  Indeed, there is evidence that there may be quantitative differences between 
various types of apoptotic cells.  It is well known that mice with defects in apoptotic 
pathways mediated through Fas and FasL develop autoimmune disease (122).  
Specifically inhibiting DC apoptosis, but not lymphocyte apoptosis, leads to autoimmune 
disease, suggesting a unique role for DC apoptosis in the maintenance of tolerance (123).  
Moreover, when viable DCs internalize apoptotic, but not necrotic DCs, they become 
resistant to LPS maturation (124) and generate antigen-specific Foxp3+ Tregs (124, 125).  
The induction of Tregs is a direct result of TGF-β1 secretion by viable DCs (122), 
previously shown to be necessary for the differentiation of naïve T-lymphocytes into 
Tregs (42, 43).   
 Macrophages also secrete TGF-β1 after ingesting apoptotic cells, and this TGF-
β1 production is dependent on phosphatidylserine (126).  Interestingly however, the 
internalization of apoptotic splenocytes by viable DCs does not induce TGF-β1 
production (124, 125).  Given that apoptotic splenocytes display phosphatidylserine, this 




by viable DCs after internalization of apoptotic DCs, as well as the presence of key 
molecular differences between apoptotic DCs and non-DC apoptotic cells (122, 127).  
The unique receptors mediating TGF-β1 secretion after the uptake of apoptotic DCs are 
unknown, but may involve highly specific receptors, possibly αβ integrins, only 
expressed on the surface of apoptotic DCs (122, 127).  The production of TGF-β mRNA 
transcripts in this present study were higher in PUVA-DCs than in untreated MoDCs 
exposed to ApoL (3.4-fold vs. 2.1-fold above untreated MoDCs, respectively), suggesting 
that the internalization of apoptotic MoDCs by viable MoDCs may have played a role in 
the induction of GILZ and transcription of TGF-β mRNA. 
 DCs expressing GILZ at high levels have been shown to generate antigen-specific 
Tregs, and GILZ, IL-10 and TGF-β are all necessary for this induction (42, 43, 69).  
Although this study did not specifically analyze Treg responses, MoDCs expressing 
GILZ increased production of IL-10 at both the protein and mRNA level, and increased 
TGF-β at the mRNA level.  Given that an intravenous infusion of PUVA-treated 
apoptotic cells induces antigen-specific Tregs in vivo (31, 46, 47), it is reasonable that 
MoDCs expressing GILZ, and secreting IL-10 and TGF-β, would also be capable of 
inducing Tregs.  Further studies will be needed to explore the possibility that MoDCs 
treated with PUVA, and/or exposed to ApoL, are capable of inducing Tregs in a similar 
fashion as Dex-DCs (69).   
 Both PUVA, and/or exposure to ApoL, induced GILZ expression to levels 
comparable with previous reports in human DCs (see Figure 5B) .  Up-regulation of 
GILZ mRNA was confirmed by increased levels of GILZ protein, as assessed by 




protein level did not follow the same trend as for GILZ mRNA up-regulation.  This is 
most likely due to the fact that protein expression was only analyzed 24 hr after 
treatment, and the kinetics of both GILZ mRNA and protein up-regulation and stability 
varied depending on the specific type of treatment.  Dex-DCs maximally up-regulated 
GILZ mRNA within 2 hr of treatment (see Figure 1E), and demonstrated the highest 
protein level after 24 hrs.  In contrast, PUVA-DCs maximally up-regulated GILZ mRNA 
24 hr after treatment, and therefore the protein level was found to be lower than that of 
Dex-DCs at the same time point.  Lastly, MoDCs exposed to ApoL would be expected to 
have the slowest induction of GILZ mRNA and protein, given the requirement for 
phosphatidylserine exposure on lymphocytes, followed by recognition and processing by 
MoDCs.  This may help explain why after 24 hr the GILZ mRNA levels were highest in 
MoDCs exposed to ApoL, but the proteins levels did not yet reflect this elevated mRNA 
expression.  It would be useful to assess GILZ protein induction at earlier and later time 
points to more definitively clarify the kinetics of protein induction. 
 In addition, MoDCs expressing high levels of GILZ produced more IL-10 (see 
Figure 6A), and produced lesser amounts of various pro-inflammatory cytokines, 
including IL-12, IL-6, TNF-α, and IFN-γ (see Figure 6B, 6C).  GILZ was necessary for 
the conversion to a tolerogenic cytokine profile, as evidenced by a reduction in IL-10 
production, and an increase in IL-12p70 production, following transient siRNA-mediated 
GILZ knockdown (see Figure 7B, 7C).  IL-12, IL-6, TNF-α, and IFN-γ are all 
inflammatory mediators released by immunogenic MoDCs in response to TLR ligation 
(34, 35).  These cytokines polarize the immune response towards an inflammatory state, 




MoDCs expressing high levels of GILZ also produced lesser amounts of various pro-
inflammatory chemokines, including IL-8, MCP-1 (CCL2), MIP-1β (CCL4), and 
RANTES (CCL5) (see Figure 6D, 6E).  These data support an earlier study in a 
monocytic cell line (THP-1), showing that GILZ expression reduced the production of 
both MIP-1α (CCL3) and RANTES (CCL5) (62).  These chemokines are also produced 
by immunogenic MoDCs in response to TLR ligation, and they function as chemotactic 
factors, recruiting immune cells such as neutrophils, natural killer cells and T-
lymphocytes to sites of inflammation or infection (34, 35).     
 This dualistic pattern of cytokine release, with reduced production of pro-
inflammatory cytokines and increased production of anti-inflammatory cytokines, is 
central to UVB-induced, PUVA-induced, and ECP-induced immunomodulation (1).  
UVB induces IL-10 release from keratinocytes (128), and PUVA has been shown to 
significantly reduce the production of IL-6, IL-8, IL-1β and TNF-α (129).  Likewise, in 
patients with chronic GVHD, ECP increases production of IL-10 (21, 51, 52) and IL-1Ra 
(21, 51, 52), and DCs cultured post-ECP produce no detectable levels of IL-1, IL-6 or IL-
12 (21).  While the general trend for reduced pro-inflammatory molecule production held 
true for all MoDCs demonstrating significant GILZ up-regulation, some groups did not 
achieve statistically significant reductions for individual cytokines and chemokines.  This 
was most likely due to biological variability between individuals, and given a larger 
sample size, all groups would have likely achieved statistically significant reductions for 
all cytokines and chemokines.  Lastly, PUVA could theoretically have globally 




unlikely given increased IL-10 production in the same MoDCs displaying reduced pro-
inflammatory molecule production. 
 
 
5.5.   Implications for Extracorporeal Photochemotherapy 
 
 The results presented in this in vitro model of ECP have potentially important 
implications for the in vivo mechanisms operating after ECP.  The vast majority of ECP-
treated cells travel to either the spleen or liver following intravenous infusion (81).  
Splenic marginal zone DCs ingest circulating apoptotic cells as soon as 1 hr after 
intravenous injection (130), and in a different report, the highest percentage of splenic 
immature DCs with internalized apoptotic cells was detected 18 hr after injection (31).  
Although the mechanisms directing ECP-treated cells towards these anatomical locations 
are not known, the marginal zone of the spleen, in particular, contains abundant APCs 
capable of interacting with T-lymphocytes circulating through the spleen (81).  It is 
conceivable that reinfusion of ECP-treated ApoL, and subsequent in vivo interactions 
with untreated tissue-resident splenic DCs, may induce GILZ expression and generate 
tolerogenic DCs capable of mediating antigen-specific immunosuppression.  This would 
be analogous to the in vivo induction of GILZ within tissue-resident DCs after systemic 
glucocorticoid administration (59).  It also points toward the marginal zone of the spleen 
as being the central anatomical location for tolerance induction elicited by ECP-treated 
apoptotic cells.  Moreover, the liver has been broadly implicated as an anatomically 
important site for tolerance induction (110, 131), as antigen-triggered apoptosis results in 




 In addition, the ECP procedure itself, through a combination of leukapheresis, 
flow dynamics on the plastic exposure plate, and interactions with platelets or other 
serum proteins, induces monocyte-to-DC differentiation (29).  It is plausible that the 
effects of PUVA revealed by our in vitro study initiate a chain of events culminating in 
GILZ induction and the modulation of differentiating MoDCs.  Interestingly, PUVA-DCs 
exposed to ApoL up-regulated GILZ to higher levels than either untreated MoDCs 
exposed to ApoL, or PUVA-DCs alone, suggesting a synergistic effect between PUVA 
treatment and ApoL exposure (see Figure 5B).  It is tempting to speculate that PUVA 
may pre-condition MoDCs for the subsequent processing of ApoL, possibly by increasing 
the phagocytic capacity of differentiating MoDCs by up-regulating thrombospondin 
receptors (CD36) (133), TAM receptors, or other scavenger receptors.  Given the 
synergism observed between PUVA-DCs and exposure to ApoL in regards to GILZ 
induction, MoDCs produced during the ECP procedure may also be uniquely pre-
conditioned by PUVA treatment to generate tolerogenic immune responses in vivo. 
 In clinical use, patients’ PBMC are exposed to UVA light as they pass 
extracorporeally through a thin exposure plate (7).  While the centrifugation process to 
isolate PBMC from other cell types is quite efficient, there are still contaminating red 
blood cells flowing through the exposure plate that are capable of absorbing UVA 
radiation.  Moreover, assuming laminar flow, cells in the center of the plate will flow 
faster than cells on the periphery.  As a result of the plate’s small, but non-zero thickness, 
laminar flow mechanics, and red cell contamination, it is possible that populations of 
monocytes, DCs, and differentiating MoDCs may be exposed to different amounts of 




be modulated in subtle ways during the procedure, and may have different in vivo effects 
after reinfusion.  Extrapolating from the data presented in this study, if a MoDC received 
a slightly smaller amount of UVA light energy, it may induce GILZ expression and be 
polarized towards the tolerogenic pathway.  If a second MoDC received slightly more 
UVA light energy, it may enter the apoptotic pathway after reinfusion into the patient.  
The net result would be a complex interaction of cells in vivo, where MoDCs modulated 
to varying degrees would be mediating the final clinical response. 
 Two recent studies highlight the pivotal role for DCs in mediating in vivo 
tolerogenic responses after ECP.  Firstly, Divito et al. challenged the conventional view 
that tolerogenic DCs suppress allograft rejection by interacting directly with anti-donor 
T-lymphocytes in vivo (134).  This group demonstrated that an infusion of tolerogenic 
DCs prolonged heart allograft survival not by directly interacting with T-lymphocytes in 
vivo, but by being re-processed by recipient DCs (134) .  The authors suggest that 
infusions of DCs are short-lived in vivo, and act as antigen-transporting cells, rather than 
APCs, to prolong allograft survival (134).  This model supports the hypothesis that GILZ 
induction within tissue-resident DCs may be the initial event leading to tolerogenic 
responses observed after reinfusion of ECP-treated cells.  Furthermore, it lends credence 
to the possibility that a small percentage of ECP-treated MoDCs undergoing early 
apoptosis are transmitting distinct tolerogenic signals (122-125) leading to GILZ up-
regulation, and that the immunosuppressive signals are not transmitted solely by ApoL. 
 Secondly, a murine model of contact hypersensitivity demonstrated that the cell-
mediated inhibition of a hapten immune response was lost when PUVA-treated 




were depleted of CD11c+ DCs prior to their adoptive transfer into naïve mice (31).  The 
tolerance was antigen-specific, as the naïve recipient mice retained the ability to properly 
respond to an unrelated hapten (31).  Strikingly, there was still cell-mediated and antigen-
specific inhibition of the same hapten immune response when PUVA-treated splenocytes 
and lymph node cells from DNFB-sensitized donors were instead depleted of CD3+ 
lymphocytes (31).  This implies, in this hapten model, that PUVA-treated CD11c+ DCs 
are the primary and relevant cellular target for ECP in mediating tolerogenic responses in 
vivo. 
   Furthermore, the adoptive transfer of cells from primary recipients that had 
received ECP-treated cells significantly suppressed the DNFB response in secondary 
recipients, but the transfer capability was lost when the cells were depleted of CD4+ or 
CD25+ populations (31).  Taken together, these results demonstrate that not only are the 
CD11c+ DCs the primary cellular target of ECP, but they induce antigen-specific 
CD4+CD25+ Tregs in vivo (31).  The hapten model does have the limitation that the 
antigen must be physically linked to the apoptotic cell, and only APCs retain this capacity 
for a long enough time in vivo to transmit meaningful tolerogenic signals (31).  In other, 
non-haptenated models, ECP-treated APCs may not be as critical for the induction of 
tolerance, as has been demonstrated with other in vivo models of ECP (45-47). 
 Returning to the fundamental mystery surrounding ECP’s clinical efficacy in 
CTCL (7), GVHD (8), allograft rejection (9), and autoimmune disease (10), it is 
worthwhile to consider how differences in immune responses may result from the 
intrinsic properties of patients’ circulating lymphocytes.  Varying percentages of 




patients with CTCL (135).  This percentage can be particularly high if the patient has the 
leukemic variant of CTCL, known as Sézary syndrome (135, 136).  Sézary cells are 
fundamentally abnormal.  They possess numerous genetic mutations, gene deletions, and 
chromosomal translocations (137).  They also have abnormal apoptotic pathways (138-
140), and are insensitive to many traditional T-lymphocyte mitogens (141).  In contrast, 
patients with GVHD, allograft rejection, and autoimmune disease, all have numerous 
benign, auto-reactive circulating lymphocytes.  These are fundamentally normal 
lymphocytes performing their specialized functions, albeit they are targeting self-tissues 
or allogeneic grafts and inflicting tissue damage in the process.  As such, it is not 
unreasonable to speculate that the responses of malignant Sézary cells and benign auto-
reactive lymphocytes to ECP may be vastly different, and translate into distinct immune 
responses.     
 The kinetics of apoptotic induction, and the activation state of the apoptotic cell, 
both play a key role in influencing the immunogenicity or tolerogenicity of the apoptotic 
stimulus (110).  Given their numerous genetic and apoptotic pathway abnormalities (137-
140), Sézary cells may rapidly undergo apoptosis in large numbers after ECP, effectively 
outstripping the phagocytic capacity of DCs to ingest and process them.  Sézary cells 
would then become secondarily necrotic and release numerous DAMPs and 
immunogenic factors (115).  Upon reinfusion into the patient, apoptotic Sézary cells, in 
combination with these pro-inflammatory mediators, would polarize an immunogenic Th1 
and cytotoxic T-lymphocyte immune response to target and eradicate the malignant cells 
(136).  Alternatively, given aberrant apoptotic pathways, Sézary cells may not possess the 




immunogenic apoptotic cell (115).  It has also been shown that anti-CD3-activated T-
lymphocytes express CD154, which converts a normally tolerogenic apoptotic 
lymphocyte into an immunogenic stimulus (142).  Interestingly, Sézary cells express 
many activation markers, including CD45RO (135), CD25 (135), and STAT3 (143), and 
the malignant cells’ persistent state of activation may play a role in the pathogenesis of 
CTCL (135).  In summary, the rapid and wide-spread induction of apoptosis, release of 
DAMPs, and the persistent activation state of Sézary cells, may all play a role in 
polarizing an immunogenic response after ECP in patients with CTCL. 
   On the other hand, auto-reactive T-lymphocytes may undergo a controlled, slower 
apoptotic cell death after ECP, producing immunosuppressive membrane blebs (111) that 
are efficiently cleared by DCs before becoming secondarily necrotic and releasing 
DAMPs.  The net in vivo effect would be the induction of GILZ within tissue-resident 
DCs, possibly in the spleen or liver, the subsequent generation of tolerogenic DCs, and 
the induction of antigen-specific immune tolerance through Treg generation.  
Investigating the differing susceptibilities of Sézary cells from CTCL patients, and auto-
reactive lymphocytes from GVHD patients, including the kinetics of cell death following 
ECP and the release of pro-inflammatory mediators, may shed light on this central 
unanswered question regarding the immunodulation observed after ECP. 
 
5.6.   Concluding Remarks 
 
 In conclusion, PUVA acts directly, and indirectly via the generation of ApoL, to 
induce GILZ expression and polarize MoDCs towards a tolerogenic phenotype and 




expression of co-stimulatory molecules and resistance to full maturation by LPS.  
MoDCs expressing GILZ are characterized functionally by increased production of 
immunosuppressive cytokines, and reduced production of pro-inflammatory cytokines 
and chemokines.  GILZ is necessary for the PUVA-mediated generation of this 
tolerogenic cytokine profile in MoDCs, as IL-10 production was decreased and IL-12 
production was increased following transient siRNA-mediated knockdown of GILZ.   
 This study provides a molecular explanation for the immunosuppressive signals 
delivered by PUVA and apoptotic cells, and contributes towards explaining how ECP can 
generate antigen-specific immunosuppression.  It also links PUVA and apoptotic cells 
with glucocorticoids, IL-10 and TGF-β.  All share a common mechanism for immune 
regulation at the level of GILZ induction and inhibition of NF-κB and other pro-
inflammatory signaling pathways.  The critical difference between ECP and 
glucocorticoid therapy lies in the steroid-sparing action of both PUVA and apoptotic 
cells.  ECP induces antigen-specific immunomodulation, thereby protecting the patient 
from the side effects of chronic steroid therapy, including an increased rate of infection 
and malignancy, adverse metabolic effects, and detrimental effects on bone and 
endocrine health (70, 71).   
 It will be important to determine whether the two PUVA-mediated methods of 
GILZ induction that we have identified can form the basis for novel therapeutic design.  
If the answer is affirmative, then over 20 years of clinical experience with ECP will be a 
lucrative source for these derived advances.  ECP could form the basis for strategies 




therapeutic avenue to promote the induction and maintenance of tolerance in GVHD, 
allograft rejection, and autoimmune diseases (144).   
 Furthermore, DC vaccines are capable of generating proficient anti-tumor 
responses in vitro, but have failed to produce durable clinical responses.  A principle 
reason for this universal shortcoming is the inhibitory microenvironment established by 
tumors that provides a powerful, suppressive influence on the anti-tumor immune 
response (145).  A recent study even revealed that the tumor microenvironment induced 
GILZ expression within DCs found at the site of tumors, thereby suppressing their anti-
tumor immunogenic activity (145).  Interestingly, blocking GILZ within DC vaccines 
prolonged the survival of mice with a pre-existing tolerogenic tumor microenvironment 
(145).  This study suggests that selectively blocking GILZ activation may represent a 
novel strategy to translate the in vitro anti-tumor responses observed with DC vaccines 
into durable in vivo clinical responses.  Continued investigation into the mechanism of 
ECP may shed light on how to modify and enhance the therapy to selectively activate 
GILZ in diseases of auto-reactive lymphocytes, and turn off GILZ in the design of DC 
vaccines for solid-tumor immunotherapy.   
 From reports of the ancient Egyptians using the Ammi majus plant growing 
alongside the Nile River to treat skin disease, to the characterization of its active 
component as a psoralen, UVA radiation combined with photosensitizing psoralens has 
remained an effective dermatologic therapy.  ECP has the potential to polarize DCs 
towards a tolerogenic or immunogenic pathway by simply switching GILZ on or off 
depending on which type of immunomodulation is desired for a given disease.  It is 




radiation to selectively stimulate the immune response to target cancer in CTCL, 
malignant melanoma, and other solid-organ tumors, and selectively suppress the immune 
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